Nothing Special   »   [go: up one dir, main page]

US20040191922A1 - Method and apparatus for desorption and ionization of analytes - Google Patents

Method and apparatus for desorption and ionization of analytes Download PDF

Info

Publication number
US20040191922A1
US20040191922A1 US10/728,442 US72844203A US2004191922A1 US 20040191922 A1 US20040191922 A1 US 20040191922A1 US 72844203 A US72844203 A US 72844203A US 2004191922 A1 US2004191922 A1 US 2004191922A1
Authority
US
United States
Prior art keywords
analyte molecules
analyte
affinity reagent
probe tip
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/728,442
Inventor
T. Hutchens
Tai-Tung Yip
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/728,442 priority Critical patent/US20040191922A1/en
Publication of US20040191922A1 publication Critical patent/US20040191922A1/en
Priority to US11/347,495 priority patent/US7449150B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • HELECTRICITY
    • H01ELECTRIC ELEMENTS
    • H01JELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00Particle spectrometers or separator tubes
    • H01J49/02Details
    • H01J49/04Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locks; Arrangements for external adjustment of electron- or ion-optical components
    • H01J49/0409Sample holders or containers
    • H01J49/0418Sample holders or containers for laser desorption, e.g. matrix-assisted laser desorption/ionisation [MALDI] plates or surface enhanced laser desorption/ionisation [SELDI] plates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/28Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40Concentrating samples
    • G01N1/405Concentrating samples by adsorption or absorption
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry
    • G01N33/6851Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/24Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
    • Y10T436/255Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.] including use of a solid sorbent, semipermeable membrane, or liquid extraction

Definitions

  • This invention relates generally to methods and apparatus for desorption and ionization of analytes for the purpose of subsequent scientific analysis by such methods, for example, as mass spectrometry or biosensors. More specifically, this invention relates to the field of mass spectrometry, especially to the type of matrix-assisted laser desorption/ionization, time-of-flight mass spectrometry used to analyze macromolecules, such as proteins or biomolecules.
  • analysis by mass spectrometry involves the vaporization and ionization of a small sample of material, using a high energy source, such as a laser, including a laser beam.
  • a high energy source such as a laser
  • the material is vaporized from the surface of a probe tip by the laser beam, and in the process, some of the individual molecules are ionized by the gain of a proton.
  • the positively charged ionized molecules are then accelerated through a short high voltage field and let fly into a high vacuum chamber, at the far end of which they strike a sensitive detector surface.
  • the time of flight is a function of the mass of the ionized molecule
  • the elapsed time between ionization and impact can be used to determine the molecule's mass which, in turn, can be used to identify the presence or absence of known molecules of specific mass.
  • analyte fluids are available only in extremely small volumes (microliters) and may be needed for performing several different analyses. Therefore, even the small amount needed for preparation of the analyte/matrix crystalline mixture for a single analysis may be significant. Also, only a tiny fraction (a few thousandths or less) of analyte used in preparing the analyte/matrix mixture for use on the probe tip is actually consumed in the mass spectrometry analysis. Any improvement in the prior art procedure which made it possible to use much less analyte to conduct the test would be highly advantageous in many clinical areas.
  • the analyte protein, or other macromolecule, used in preparing the analyte matrix for use on the probe tip is not suitable for any subsequent chemical tests or procedures because it is bound up in the matrix material.
  • all of the matrix material used to date is strongly acidic, so that it would affect many chemical reactions which might be attempted on the mixture in order to modify the analyte molecules for subsequent examination. Any improvement in the procedure which made it possible to conduct subsequent chemical modifications or reactions on the analyte molecules, without removing them from the matrix or the probe tip, would be of enormous benefit to researchers and clinicians.
  • matrix adduct formation of analyte-matrix complex which interferes with the accuracy of analyte measurement
  • the primary object of the invention is to provide improved methods, materials composition and apparatus for coupled adsorption, desorption and ionization of multiple or selected analytes into the gas (vapor) phase, preferably for use in conjunction with mass spectrometry of biomolecules and other macromolecules, as well as by means of analytic detection other than mass spectrometry.
  • the invention incudes a flexible variety of options for presenting surfaces with attached energy absorbing molecules, defined reaction sites, and affinity reagents for the capture,e transfer, and/or the desorption of analytes before and after a sseries of chemical, physical, and/or enzymatic modifications performed in situ.
  • Another object is to provide such a method and apparatus for affinity-directed detection of analytes, including desorption and ionization of analytes in which the analyte is not dispersed in a matrix solution or crystalline structure but is presented within, on or above an attached surface of energy absorbing “matrix” material through molecular recognition events, in a position where it is accessible and amenable to a wide variety of chemical, physical and biological modification or recognition reactions.
  • the probe surface with and without bonded energy absorbing molecules referred to as the sample presenting surface can be composed of a variety of materials, including porous or nonporous materials, with the porous materials providing sponge-like, polymeric, high surface areas for optimized adsorption and presentation of analyte.
  • These surface materials can be substituted (at varying densities) with chemically bonded (covalent or noncovalent) affinity adsorption reagents and/or chemically bonded (i.e., immobilized) energy absorbing molecules (bound “matrix” molecules).
  • the geometry of the sample presenting surface can be varied (i.e., size, texture, flexibility, thickness, etc.) to suit the need (e.g., insertion into a living organism through spaces of predetermined sizes) of the experiment (assay).
  • Another object is to provide such a method and apparatus in which the analyte material is chemically bound or physically adhered to a substrate forming a probe tip or other sample presenting surface.
  • a further object is to provide means for the modification of probe or sample presenting surfaces with energy-absorbing molecules to enable the successful desorption of analyte molecules without the addition of exogenous matrix molecules as in prior art.
  • a further object is to provide the appropriate density of energy-absorbing molecules bonded (covalently or noncovalently) in a variety of geometries such that mono layers and multiple layers of attached energy-absorbing molecules can be used to facilitate the desorption of analyte molecules of varying masses.
  • the optimum ratio of adsorbed or bonded energy-absorbing molecules to analyte varies with the mass of the analyte to be detected.
  • a further object is to modify the sample presenting surface with such energy-absorbing molecules where the composition of the probe or sample presenting surface is other than the metal or metallic surfaces as described in prior art.
  • a further object is to provide all combinations of surfaces modified with energy-absorbing molecules and/or affinity-directed analyte capture devices to enable the selective and/or nonselective adsorption of analytes and the subsequent desorption either with or without requiring the subsequent addition of additional matrix molecules. It is important to note that the surfaces modified with affinity reagents for the capture of analytes are-more useful than the underivitized sample surfaces described in prior art even when the deposition of energy-absorbing molecules (that is matrix) is as described in prior art. Because of the advantages in the ability to remove contaminating substances from the adsorbed analyte molecules and because of the ability to modify adsorbed analyte molecules without (or before) added matrix.
  • a further object is to provide such a method and apparatus in which the substrate forming the probe tip or other sample presenting surface is derivatized with one or more affinity reagents (a variety of densities and degrees of amplification) for selective bonding with predetermined analytes or classes of analytes.
  • affinity reagents a variety of densities and degrees of amplification
  • a further object is to provide methods and apparatus for using probe tips having surfaces derivatized with affinity reagents and containing laser desorption matrix material (chemically bonded to surface or not) which may be used to isolate target analyte materials from undifferentiated biological samples such as blood, tears, urine, saliva, gastrointestinal fluids, spinal fluid, amniotic fluid, bone marrow, bacteria, viruses, cells in culture, biopsy tissue, plant tissue or fluids, insect tissue or fluids, etc.
  • undifferentiated biological samples such as blood, tears, urine, saliva, gastrointestinal fluids, spinal fluid, amniotic fluid, bone marrow, bacteria, viruses, cells in culture, biopsy tissue, plant tissue or fluids, insect tissue or fluids, etc.
  • a further object is to use analyte detection methods other than the generic electron multipliers typically used in mass spectrometric devices. This would include but would not be limited to detection films/plates for the qualitative or quantitative evaluation of fluorescent or radio-labeled anialytes or analyte molecule complexes.
  • a further object is to provide such a system in which the affinity reagent chemically bonds or biologically adheres to the target analyte or class of analytes.
  • a further object is to use existing and new solid phase affinity reagents (e.g., small diameter porous or nonporous beads of crosslineated polymer with attached molecular capture devices) designed for the (1) capture (adsorption of one or more analytes, (2) the preparation of these captured analytes (e.g., washing with H 2 O or other buffered or nonbuffered solutions to remove contaminants such as salts, multiple cycles of washing, such as with polar organic solvent, detergent-dissolving solvent, dilute acid, dilute base or urea), and (3) most importantly, the direct transfer of these captured and prepared analytes to the probe surface for subsequent analyte desorption (for detection, quantification and/or mass analysis).
  • solid phase affinity reagents e.g., small diameter porous or nonporous beads of crosslineated polymer with attached molecular capture devices designed for the (1) capture (adsorption of one or more analytes, (2) the preparation of these captured analytes (e.g., washing with H
  • a further object is to provide such a system in which the predetermined analytes are individual biomolecules or other macromolecules or combinations of adjoined molecules (i.e., complexes).
  • a still further object is to provide such a method and apparatus in which the matrix materials used are not strongly acidic, as in prior art matrices, but are chemically modified into the slightly acidic, neutral pH or strongly basic range of pH.
  • a further object is to provide such a system in which the matrix material has a pH above 6.0.
  • a still further object is to provide a method and apparatus for desorption and ionization of analytes in which unused portion of the analytes contained on the presenting surface remain chemically accessible, so that a series of chemical and/or enzymatic or other treatments (e.g., discovery of analyte-associated molecules by molecular recognition) of the analyte may be conducted on the probe tip or other presenting surface, in situ, followed by sequential analyses of the modified analyte by mass spectrometry.
  • the analyte is adsorbed to the sample presenting surface and can be treated (modified in situ after the excess free matrix is removed (i.e., washed away).
  • Matrix can be added back before analysis by mass spectrometry. Using this procedure, an analyte can be repeatedly tested for a variety of components by removing one matrix, modifying the analyte sample, re-applying the same or different matrix, analyzing the sample, etc.
  • a further object is to provide a method and apparatus for the combined chemical and/or enzymatic modifications of target analytes for the purpose of elucidating primary, secondary, tertiary, or quaternary structure of the analyte and its components.
  • a still further object is to provide such a method and apparatus in which the probe tips or other sample presenting surfaces are formed of a variety of materials, including electrically insulating materials (porous and nonporous), flexible or nonrigid materials, optically transparent materials (e.g., glass, including glass of varying densities, thicknesses, colors and with varying refractive indices), as well as less reactive, more biocompatible materials (e.g., biopolymers such as agarose, dextran, cellulose, starches, peptides, and fragments of proteins and of nucleic acids such as DNA (deoxyribonucleic acid) and RNA (ribonucleic acid). These surfaces can be chemically modified by the attachment of energy-absorbing molecules and/or affinity directed analyte capture molecules.
  • Another object is to provide a method and apparatus for desorption and ionization of analyte materials in which cations other than protons (H + ) are utilized for ionization of analyte macromolecules.
  • the laser or light source used to convey energy to the probe surface can employ a wavelength(s) that is(are) not fixed but can be varied according to the wavelength absorbed by the matrix (whether the matrix is added in the free form or is chemically bonded to the probe (sample presenting) surface).
  • a variety of wavelengths (10 or more) defined by absorbance of matrix or energy absorbing surface can be utilized.
  • Another object is to provide such a method and apparatus in which the probe tips or other sample presenting surfaces used for laser desorption/ionization time-of-flight mass spectrometry are magnetized and in which the matrix, affinity directed absorption molecules and/or analyte materials are magnetically adhered to such magnetized surface.
  • a further object is a method and apparatus in which the matrix and/or analyte materials are adhered by any variety of chemical mechanisms to the sample presenting surface.
  • a further objective is to provide energy-absorbing molecules which have been incorporated into other chemical structures (e.g., chemical or biological polymers) for the deposition (covalent or noncovalent) onto the sample presenting surface in a way that enables repetitious analyte desorption events without interference with chemical and/or enzymatic modifications of the analyte molecule(s) performed in situ.
  • chemical structures e.g., chemical or biological polymers
  • Another object is to provide sample presenting surfaces in a variety of sizes and configurations (up to 4“ ⁇ 4”) with multiple (up to 10,000 or more) spots (including spots down to ⁇ 0.001 inch diameter) of affinity reagents arranged in predetermined arrays for the selective adsorption of numerous different analytes (e.g., clinical chemical marker proteins) to enable a wide spectrum sampling of the macromolecular composition of biological samples/fluids.
  • numerous different analytes e.g., clinical chemical marker proteins
  • the present invention overcomes limitations and disabilities of the prior art by providing probe tips or sample plates whose surfaces have been derivatized with biospecific affinity reagents which will selectively bind specific groups or types of biomolecules or other analytes out of an undifferentiated sample (such as blood or urine).
  • an undifferentiated sample such as blood or urine.
  • Appropriate selection of the affinity reagents used to derivatize the probe tip surface therefore makes possible the selection from the undifferentiated sample and binding to the probe tip of the specific types or groups of biological or other macromolecules under investigation, or subsequent examination (e.g., quantification and/or structure elucidation) by mass spectrometry.
  • probe tips used in the process of the invention need not be metal or metal-coated, as with prior art procedures.
  • Research involved in the invention has involved glass and synthetic polymer surfaces such as polystyrene, polypropylene, polyethylene, polycarbonate and other polymers including biopolymers, for the probe tips which have been covalently or noncovalently derivatized for immobilization of specific reagents that will direct the selective adsorption of specific analytes.
  • These surfaces will include immobilized metal ions, immobilized proteins, peptides, enzymes, and inhibitor molecules, immobilized DNA and RNA, immobilized antibodies, immobilized reducing agents, immobilized carbohydrates and lectins, immobilized dyes and immobilized protein surface domains involved in molecular recognition (e.g., dimerization domains and subunits).
  • the preferred probe tip, or sample plate, for selective adsorption/presentation of sample for mass analysis are (1) stainless steel (or other metal) with a synthetic polymer coating (e.g., cross-linked dextran or agarose, nylon, polyethylene, polystyrene) suitable for covalent attachment of specific biomolecules or other nonbiological affinity reagents, (2) glass or ceramic, and/or (3) plastic (synthetic polymer).
  • a synthetic polymer coating e.g., cross-linked dextran or agarose, nylon, polyethylene, polystyrene
  • plastic synthetic polymer
  • Two features of the invention are (1) the specific size and localization of the derivatized surface with respect to the laser beam and (2) the affinity directed presentation of specific analyte molecules (e.g., macromolecule or biopolymer) at a defined surface density or local concentration required for the efficient detection by laser desorption/ionization time-of-flight mass spectrometry.
  • This can be accomplished by arranging the affinity adsorption “spots” (0.005 to 0.080 inch diameter) on the probe surface in a defined manner (400 to 1,000 spots could be placed on a surface about the size of a glass slide).
  • pH modified chemical matrices can be used on these surfaces to facilitate desorption/ionization without disruption of conditions necessary for subsequent sample modification.
  • prior art matrix materials used for biomolecular mass spectrometry are acidic.
  • the exact chemical structure of the pH-modified matrices still are unknown.
  • suitable neutralization of the matrix material it can be made largely passive to subsequent chemical or enzymatic reactions carried out on the analyte molecules presented on the derivatized probe tip surface by the biospecific affinity reagents. This makes possible the carrying out of chemical reactions on the analyte molecules presented on the probe tips.
  • FIG. 1A is a mass spectrum of peptide mixtures using sinapinic acid pH 6.5 as the matrix.
  • FIG. 1B is a mass spectrum of the same peptide mixtures after in situ addition of CuSO 4 .
  • FIG. 2A is a mass spectrum of human casein phosphopeptide (R1-K18+5P) using sinapinic acid pH 6.5 as the matrix.
  • FIG. 2B shows the mass spectrum of the same peptide after in situ alkaline phosphatase digestion for 5 and 10 min respectively.
  • FIG. 2D shows the mass spectrum of the same peptide using dihydroxybenzoic acid pH 2 as the matrix, after in situ alkaline phosphatase digestion for 10 min.
  • FIG. 3 is a mass spectrum histidine-rich glycoprotein (GHHPH) 5 G peptide using sinapinic acid pH 6.2 as the matrix before and after in situ digestion with carboxypeptidase P.
  • FIG. 4 is a composite mass spectra of peptide mixtures using sinapinic acid as the matrix on glass, polypropylene-coated steel, polystyrene-coated steel and nylon probe tips.
  • FIG. 5A is a mass spectrum of peptides unadsorbed by TSK SW-IDA-Cu(II).
  • FIG. 5B is a mass spectrum of peptide adsorbed by TSK SW-IDA-Cu(II).
  • FIG. 5C is a mass spectrum of the same peptide adsorbed on TSK SW-IDA-Cu(II) after water wash.
  • FIG. 6 is a mass spectrum of myoglobin ( ⁇ 8 fmole) affinity-adsorbed on TSK SW-IDA-Cu(II).
  • FIG. 7A is a mass spectrum of proteins/peptides in infant formula.
  • FIG. 7B is a mass spectrum of phosphopeptides in the same sample affinity-adsorbed on Sepharose-TED-Fe(III).
  • FIG. 7C is a mass spectrum of proteins/peptides in gastric aspirate of preterm infant.
  • FIG. 7D is a mass spectrum of the phosphopeptides in the same sample adsorbed on Sepharose-TED-Fe(III).
  • FIG. 8 (bottom) is a mass spectrum of rabbit anti-human lactoferrin immunoglobin affinity adsorbed on paramagnetic Dynabead-sheep anti-rabbit IgG.
  • FIG. 8 (top) is a mass spectrum of human lactoferrin and rabbit anti-human lactoferrin IgG complex affinity adsorbed on paramagmetic Dynabead-sheep anti-rabbit IgG.
  • FIG. 9 is a mass spectrum of human lactoferrin affinity adsorbed on a single bead of agarose-single-stranded DNA deposited on a 0.5 mm diameter steel probe tip.
  • FIG. 10 is the mass spectrum of human lactoferrin affinity adsorbed from urine on agarose-single-stranded DNA.
  • FIG. 11A is a mass spectrum of human gastrointestinal fluid.
  • FIG. 11B is a mass spectrum of trypsin in the same sample affinity adsorbed on AffiGel 10-soybean trypsin inhibitor.
  • FIG. 12A is a mass spectrum of human serum proteins.
  • FIG. 12B is a mass spectrum of human serum albumin in the same sample affinity adsorbed on agarose-Cibacron blue.
  • FIG. 13 is a drawing of the surface bound cinnamamide; R represents the surface plus cross-linear.
  • FIG. 14A is a mass spectrum of peptide mixtures on surface bound cinnamamide.
  • FIG. 14B shows the mass spectrum of the same peptide mixtures on free cinnamamide.
  • FIG. 15 is a drawing of the surface bound cinnamyl bromide; tvo structural forms are possible; R represents the surface plus cross-linear.
  • FIG. 16A is a mass spectrum of peptide mixtures on surface bound cinnamyl bromide.
  • FIG. 16B is a mass spectrum of the same peptide mixtures on free cinnamyl bromide.
  • FIG. 17 is a drawing of the surface bound MAP-dihydroxybenzoic acid; R represents the surface plus cross-linear.
  • FIG. 18 is a mass spectrum of peptide mixtures on surface bound MAP alone (control surface).
  • FIG. 18B is a mass spectrum of the same peptide mixtures on surface bound MAP-dihydroxybenzoic acid.
  • FIG. 19A is a mass spectrum of myoglobin on surface bound cyanohydroxycinnamic acid.
  • FIG. 19B is the same mass spectrum in the low mass region.
  • Sinapinic acid (dimethoxy hydroxycinnamic acid) (Aldrich Chemical Co., Inc., Milwaukee, Wis.) 20 mg/ml water suspension (intrinsic pH 3.88) Dihydoxybenzoic acid (Aldrich) 20 mg/ml water (intrinsic pH 2.07) Cyanohydroxycinnamic acid (Aldrich) 20 mg/ml water suspension (intrinsic pH 3.3) each titrated with triethylamine (Pierce, Rockford, Ill.) to pH 6.5, 7.2 and 6.5 respectively
  • FIG. 1 showed the in situ metal-binding properties of the peptides under neutralized condition.
  • Solid glass rod (1.5 mm dia) was cut into 1 cm segments and inserted into stainless steel probe tip support
  • Cu(II) was chelated by iminodiacetate group covalently attached to either porous agarose beads (Chelating Sepharose Fast Flow, Pharmacia Biotech Inc., Piscataway, N.J., ligand density 22-30 umole/ml gel) or solid TSK-SW beads (ToyoSoda, Japan, ligand density 20 umole/ml gel)
  • Fe(III) was chelated by tris(carboxymethyl)ethylenediamine-Sepharose 6B (synthesized as described by Yip and Hutchens, Protein Expression and Purification 2(1991)355-362, ligand density 65 umole/ml)
  • FIG. 5A showed the molecular ions (and multiple Na-adducts) of neurotensin and sperm activating factor which were not adsorbed by the IDA-Cu(II).
  • the mass spectrum in FIG. 5B showed mainly the angiotensin I plus Na-adducts.
  • the IDA-Cu(II) gel was further washed with 500 ul of water 2 ⁇ , the resulting mass spectrum showed only the parent angiotensin I species with no other adduct peaks.
  • Polyclonal rabbit anti-human lactoferrin antibody was custom generated for this lab by Bethyl Laboratories (Montgomery, Tex.). It was purified by thiophilic adsorption and then by immobilized lactoferrin column. Sheep anti-rabbit IgG covalently attached to magnetic beads were obtained from Dynal AS (Oslo, Norway) (uniform 2.8 um superparamagnetic polystyrene beads, ligand density 10 ug sheep IgG per mg bead).
  • Cibacron Blue 3GA-agarose (Type 3000, 4% beaded agarose, ligand density 2-5 umoles/ml, Sigma).
  • Other immobilized dyes include Reactive Red 120-agarose, Reactive Blue-agarose, Reactive Green-agarose, Reactive Yellow-agarose (Sigma)
  • Cinnamamide (Aldrich, not a matrix by prior art) was dissolved in isopropanol/0.5 M sodium carbonate (3:1) and mixed with divinyl sulfone (Fluka, Ronkonkoma, N.Y.) activated Sepharose (Pharmacia) at room temperature for 2 hr. The excess molecules were washed away with isopropanol.
  • the proposed structure was presented in FIG. 13. 2 ul of bound or free molecule was deposited on the probe tips, 1 ul of peptide mixtures in 0.1% TFA was added on top and the result showed the peptide ion signals detected only for the bound form.
  • Group 4 Energy Absorbing Molecule Covalently Bonded to Surface via Undetermined Group.
  • Cyanohydroxycinnamic acid was dissolved in methanol and mixed with AffiGel 10 (BioRad) at room temperature for two hours. The unbound molecules were washed away with methanol. Protein samples that are found to desorb successfully from this modified surface include myoglobin (FIG. 19), trypsin and carbonic anhydrase.
  • Presenting surface the probe tip, sample plate or other surface on which the analyte and matrix are presented for desorption/ionization and analysis for example by mass spectrometry.
  • “Matrix” as described in prior art as the substance mixed with the analyte (typically prior to deposition) and deposited on the presenting surface in association with the analyte to absorb at least part of the energy from the energy source (e.g., laser) to facilitate desorption of intact molecules of the analyte.
  • the energy source e.g., laser
  • “Affinity reagent” analyte capture device—the class of molecules (both man made, unnatural, natural and biological) and/or compounds which have the ability of being retained on the presenting surface (by covalent bonding, chemical absorption, etc.) while retaining the ability of recognition and bonding to an analyte.
  • Adduct the appearance of an additional mass associated with the analyte and usually caused by the reaction of excess matrix (or matrix break-down products) directly with the analyte.
  • “Adsorption” the chemical bonding (covalent and/or noncovalent) of the energy-absorbing molecules, the affinity reagent (i.e., analyte capture device), and/or the analyte to the probe (presenting surface).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Electron Tubes For Measurement (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Photoreceptors In Electrophotography (AREA)

Abstract

This invention relates generally to methods and apparatus for desorption and ionization of analytes for the purpose of subsequent scientific analysis by such methods, for example, as mass spectrometry or biosensors. More specifically, this invention relates to the field of mass spectrometry, especially to the type of matrix-assisted laser desorption/ionization, time-of-flight mass spectrometry used to analyze macromolecules, such as proteins or biomolecules. Most specifically, this invention relates to the sample probe geometry, sample probe composition, and sample probe surface chemistries that enable the selective capture and desorption of analytes, including intact macromolecules, directly from the probe surface into the gas (vapor) phase without added chemical matrix.

Description

  • [0001] The United States government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of Grant No. 58-6250-1-003 awarded by the United States Department of Agriculture.
  • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention. [0002]
  • This invention relates generally to methods and apparatus for desorption and ionization of analytes for the purpose of subsequent scientific analysis by such methods, for example, as mass spectrometry or biosensors. More specifically, this invention relates to the field of mass spectrometry, especially to the type of matrix-assisted laser desorption/ionization, time-of-flight mass spectrometry used to analyze macromolecules, such as proteins or biomolecules. [0003]
  • 2. Description of the Prior Art. [0004]
  • Generally, analysis by mass spectrometry involves the vaporization and ionization of a small sample of material, using a high energy source, such as a laser, including a laser beam. The material is vaporized from the surface of a probe tip by the laser beam, and in the process, some of the individual molecules are ionized by the gain of a proton. The positively charged ionized molecules are then accelerated through a short high voltage field and let fly into a high vacuum chamber, at the far end of which they strike a sensitive detector surface. Since the time of flight is a function of the mass of the ionized molecule, the elapsed time between ionization and impact can be used to determine the molecule's mass which, in turn, can be used to identify the presence or absence of known molecules of specific mass. [0005]
  • All known prior art procedures which present proteins or other large biomolecules on a probe tip for laser desorption/ionization time-of-flight mass spectrometry rely on a crystalline solid mixture of the protein or other analyte molecule in a large excess of acidic matrix material deposited on the bare surface of a metallic probe tip. (The sample probe tip typically is metallic, either stainless steel, nickel plated material or platinum). Immobilizing the analyte in such a matrix was thought to be necessary in order to prevent the destruction of analyte molecules by the laser beam. The laser beam strikes the mixture on the probe tip and its energy is used to vaporize a small portion of the matrix material along with some of the embedded analyte molecules. Without the matrix, the analyte molecules are easily fragmented by the laser energy, so that the mass, and identity, of the original macromolecule is very difficult to determine. [0006]
  • This prior art procedure has several limitations which have prevented its adaptation to automated protein or other macrobiological molecules analysis. First, in a very crude sample it is necessary to partially fractionate (or otherwise purify the sample as much as possible) to eliminate the-presence of excessive extraneous materials in the matrix/analyte crystalline mixture. The presence of large quantities of components may depress the signal of the targeted analyte. Such purification is time-consuming and expensive and would be very difficult to do in an automated analyzer. [0007]
  • Second, while the amount of analyte material needed for analysis by the prior art method is not large (typically in a picomole range), in some circumstances, such as tests on pediatric patients, analyte fluids are available only in extremely small volumes (microliters) and may be needed for performing several different analyses. Therefore, even the small amount needed for preparation of the analyte/matrix crystalline mixture for a single analysis may be significant. Also, only a tiny fraction (a few thousandths or less) of analyte used in preparing the analyte/matrix mixture for use on the probe tip is actually consumed in the mass spectrometry analysis. Any improvement in the prior art procedure which made it possible to use much less analyte to conduct the test would be highly advantageous in many clinical areas. [0008]
  • Third, the analyte protein, or other macromolecule, used in preparing the analyte matrix for use on the probe tip is not suitable for any subsequent chemical tests or procedures because it is bound up in the matrix material. Also, all of the matrix material used to date is strongly acidic, so that it would affect many chemical reactions which might be attempted on the mixture in order to modify the analyte molecules for subsequent examination. Any improvement in the procedure which made it possible to conduct subsequent chemical modifications or reactions on the analyte molecules, without removing them from the matrix or the probe tip, would be of enormous benefit to researchers and clinicians. [0009]
  • Additional limitations in the prior art included problems with matrix use such as: [0010]
  • (1) formation of analyte-matrix complex (referred to as “matrix adduct” which interferes with the accuracy of analyte measurement; [0011]
  • (2) inability to wash away contaminants present in analyte or matrix (e.g., other proteins or salts); [0012]
  • (3) formation of analyte-salt ion adducts; [0013]
  • (4) less than optimum solubility of analyte in matrix; [0014]
  • (5) signal (molecular ion) suppression “poisoning” due to simultaneous presence of multiple components; and [0015]
  • (6) selective analyte desorption/ionization. [0016]
  • There are a number of problems and limitations with the prior art methods. Prior investigators, including Karas and Hillenkamp have reported a variety of techniques for analyte detection using mass spectroscopy, but these techniques suffered because of inherent limitations in sensitivity and selectivity of the techniques, specifically including limitations in detection of analytes in low volume, undifferentiated samples. The “Hillenkamp-Karas” articles that pertain to this field of invention are:[0017]
  • 1. Hillenkamp, “Laser Desorption Mass Spectrometry: Mechanisms, Techniques and Applications”; [0018] Bordeaux Mass Spectrometry Conference Report, 1988, pages 354-362.
  • 2. Karas and Hillenkamp, “Ultraviolet Laser Desorption of Proteins Up to 120,000 Daltons”, [0019] Bordeaux Mass Spectrometry Conference Report, 1988, pages 416, 417.
  • 3. Karas and Hillenkamp, “Laser Desorption Ionization of Proteins With Molecular Masses Exceeding 10,000 Daltons”, [0020] Analytical Chemistry, 60. 2299, July 1988.
  • 4. Karas, Ingendoh, Bahr and Hillenkamp, “UV-Laser Desorption/Ionization Mass Spectrometry of Femtomol Amounts of Large Proteins”, [0021] Biomed. Environ. Mass Spectrum (in press).
  • The use of laser beams in time-of-flight mass spectrometers is shown, for example, in U.S. Pat. Nos. 4,694,167; 4,686,366, 4,295,046, and 5,045,694, incorporated by reference. [0022]
  • The first successful molecular mass measurements of intact peptides and small proteins (only up to about 15 kDa) by any form of mass spectrometry were made by bombarding surfaces with high energy particles (plasma desorption and fast atom bombardment mass spectrometry); this breakthrough came in 1981 and 1982. Improvements came in 1985 and 1986, however, yield (signal intensities), sensitivity, precision, and mass accuracy remained relatively low. Higher molecular mass proteins (about 20 to 25 kDa) were not observed except on rare occasions; proteins representing average molecular weights (approximately 70 kDa) were not ever observed with these methods. Thus, evaluation of most proteins by mass spectrometry remains unrealized. [0023]
  • In 1988, Hillenkamp and his coworkers used UV laser desorption time-of-flight mass spectrometry and discovered that when proteins of relatively high molecular mass were deposited on the probe tip in the presence of a very large molar excess of an acidic, UV absorbing chemical matrix (nicotinic acid) they could be desorbed in the intact state. This new technique is called matrix-assisted laser desorption/ionization (MALDI) time-of-flight mass spectrometry. Note that laser desorption time-of-flight mass spectrometry (without the chemical matrix) had been around for some time, however, there was little or no success determining the molecular weights of large intact biopolymers such as proteins and nucleic acids because they were fragmented (destroyed) upon desorption. Thus, prior to the introduction of a chemical matrix, laser desorption mass spectrometry was essentially useless for the detection of specific changes in the mass of intact macromolecules (see below). Note that the random formation of matrix crystals and the random inclusion of analyte molecules in the solid solution is prior art. [0024]
  • SUMMARY OF THE INVENTION
  • The primary object of the invention is to provide improved methods, materials composition and apparatus for coupled adsorption, desorption and ionization of multiple or selected analytes into the gas (vapor) phase, preferably for use in conjunction with mass spectrometry of biomolecules and other macromolecules, as well as by means of analytic detection other than mass spectrometry. The invention incudes a flexible variety of options for presenting surfaces with attached energy absorbing molecules, defined reaction sites, and affinity reagents for the capture,e transfer, and/or the desorption of analytes before and after a sseries of chemical, physical, and/or enzymatic modifications performed in situ. [0025]
  • Another object is to provide such a method and apparatus for affinity-directed detection of analytes, including desorption and ionization of analytes in which the analyte is not dispersed in a matrix solution or crystalline structure but is presented within, on or above an attached surface of energy absorbing “matrix” material through molecular recognition events, in a position where it is accessible and amenable to a wide variety of chemical, physical and biological modification or recognition reactions. [0026]
  • The probe surface with and without bonded energy absorbing molecules, referred to as the sample presenting surface can be composed of a variety of materials, including porous or nonporous materials, with the porous materials providing sponge-like, polymeric, high surface areas for optimized adsorption and presentation of analyte. [0027]
  • These surface materials can be substituted (at varying densities) with chemically bonded (covalent or noncovalent) affinity adsorption reagents and/or chemically bonded (i.e., immobilized) energy absorbing molecules (bound “matrix” molecules). The geometry of the sample presenting surface can be varied (i.e., size, texture, flexibility, thickness, etc.) to suit the need (e.g., insertion into a living organism through spaces of predetermined sizes) of the experiment (assay). [0028]
  • Another object is to provide such a method and apparatus in which the analyte material is chemically bound or physically adhered to a substrate forming a probe tip or other sample presenting surface. [0029]
  • A further object is to provide means for the modification of probe or sample presenting surfaces with energy-absorbing molecules to enable the successful desorption of analyte molecules without the addition of exogenous matrix molecules as in prior art. [0030]
  • A further object is to provide the appropriate density of energy-absorbing molecules bonded (covalently or noncovalently) in a variety of geometries such that mono layers and multiple layers of attached energy-absorbing molecules can be used to facilitate the desorption of analyte molecules of varying masses. The optimum ratio of adsorbed or bonded energy-absorbing molecules to analyte varies with the mass of the analyte to be detected. A further object is to modify the sample presenting surface with such energy-absorbing molecules where the composition of the probe or sample presenting surface is other than the metal or metallic surfaces as described in prior art. Separate from the chemical and/or physical modification of the probe surface with energy absorbing molecules is the modification-of-these surfaces with affinity reagents, both chemical and/or biological, for the specific purpose of capturing (adsorbing) specific analyte molecules or classes of analyte molecules for the subsequent preparation, modification, and successful desorption of said analyte molecules. [0031]
  • A further object is to provide all combinations of surfaces modified with energy-absorbing molecules and/or affinity-directed analyte capture devices to enable the selective and/or nonselective adsorption of analytes and the subsequent desorption either with or without requiring the subsequent addition of additional matrix molecules. It is important to note that the surfaces modified with affinity reagents for the capture of analytes are-more useful than the underivitized sample surfaces described in prior art even when the deposition of energy-absorbing molecules (that is matrix) is as described in prior art. Because of the advantages in the ability to remove contaminating substances from the adsorbed analyte molecules and because of the ability to modify adsorbed analyte molecules without (or before) added matrix. [0032]
  • A further object is to provide such a method and apparatus in which the substrate forming the probe tip or other sample presenting surface is derivatized with one or more affinity reagents (a variety of densities and degrees of amplification) for selective bonding with predetermined analytes or classes of analytes. [0033]
  • A further object is to provide methods and apparatus for using probe tips having surfaces derivatized with affinity reagents and containing laser desorption matrix material (chemically bonded to surface or not) which may be used to isolate target analyte materials from undifferentiated biological samples such as blood, tears, urine, saliva, gastrointestinal fluids, spinal fluid, amniotic fluid, bone marrow, bacteria, viruses, cells in culture, biopsy tissue, plant tissue or fluids, insect tissue or fluids, etc. [0034]
  • Because of the new and preferred method for presentation and desorption of selected analytes, a further object is to use analyte detection methods other than the generic electron multipliers typically used in mass spectrometric devices. This would include but would not be limited to detection films/plates for the qualitative or quantitative evaluation of fluorescent or radio-labeled anialytes or analyte molecule complexes. [0035]
  • A further object is to provide such a system in which the affinity reagent chemically bonds or biologically adheres to the target analyte or class of analytes. [0036]
  • A further object is to use existing and new solid phase affinity reagents (e.g., small diameter porous or nonporous beads of crosslineated polymer with attached molecular capture devices) designed for the (1) capture (adsorption of one or more analytes, (2) the preparation of these captured analytes (e.g., washing with H[0037] 2O or other buffered or nonbuffered solutions to remove contaminants such as salts, multiple cycles of washing, such as with polar organic solvent, detergent-dissolving solvent, dilute acid, dilute base or urea), and (3) most importantly, the direct transfer of these captured and prepared analytes to the probe surface for subsequent analyte desorption (for detection, quantification and/or mass analysis).
  • A further object is to provide such a system in which the predetermined analytes are individual biomolecules or other macromolecules or combinations of adjoined molecules (i.e., complexes). [0038]
  • A still further object is to provide such a method and apparatus in which the matrix materials used are not strongly acidic, as in prior art matrices, but are chemically modified into the slightly acidic, neutral pH or strongly basic range of pH. [0039]
  • A further object is to provide such a system in which the matrix material has a pH above 6.0. [0040]
  • A still further object is to provide a method and apparatus for desorption and ionization of analytes in which unused portion of the analytes contained on the presenting surface remain chemically accessible, so that a series of chemical and/or enzymatic or other treatments (e.g., discovery of analyte-associated molecules by molecular recognition) of the analyte may be conducted on the probe tip or other presenting surface, in situ, followed by sequential analyses of the modified analyte by mass spectrometry. In one case (i.e., repetitive sequential analyses) the analyte is adsorbed to the sample presenting surface and can be treated (modified in situ after the excess free matrix is removed (i.e., washed away). Matrix can be added back before analysis by mass spectrometry. Using this procedure, an analyte can be repeatedly tested for a variety of components by removing one matrix, modifying the analyte sample, re-applying the same or different matrix, analyzing the sample, etc. [0041]
  • A further object is to provide a method and apparatus for the combined chemical and/or enzymatic modifications of target analytes for the purpose of elucidating primary, secondary, tertiary, or quaternary structure of the analyte and its components. [0042]
  • A still further object is to provide such a method and apparatus in which the probe tips or other sample presenting surfaces are formed of a variety of materials, including electrically insulating materials (porous and nonporous), flexible or nonrigid materials, optically transparent materials (e.g., glass, including glass of varying densities, thicknesses, colors and with varying refractive indices), as well as less reactive, more biocompatible materials (e.g., biopolymers such as agarose, dextran, cellulose, starches, peptides, and fragments of proteins and of nucleic acids such as DNA (deoxyribonucleic acid) and RNA (ribonucleic acid). These surfaces can be chemically modified by the attachment of energy-absorbing molecules and/or affinity directed analyte capture molecules. [0043]
  • Another object is to provide a method and apparatus for desorption and ionization of analyte materials in which cations other than protons (H[0044] +) are utilized for ionization of analyte macromolecules.
  • Note that the laser or light source used to convey energy to the probe surface can employ a wavelength(s) that is(are) not fixed but can be varied according to the wavelength absorbed by the matrix (whether the matrix is added in the free form or is chemically bonded to the probe (sample presenting) surface). For this procedure, a variety of wavelengths (10 or more) defined by absorbance of matrix or energy absorbing surface can be utilized. [0045]
  • Another object is to provide such a method and apparatus in which the probe tips or other sample presenting surfaces used for laser desorption/ionization time-of-flight mass spectrometry are magnetized and in which the matrix, affinity directed absorption molecules and/or analyte materials are magnetically adhered to such magnetized surface. [0046]
  • A further object is a method and apparatus in which the matrix and/or analyte materials are adhered by any variety of chemical mechanisms to the sample presenting surface. [0047]
  • A further objective is to provide energy-absorbing molecules which have been incorporated into other chemical structures (e.g., chemical or biological polymers) for the deposition (covalent or noncovalent) onto the sample presenting surface in a way that enables repetitious analyte desorption events without interference with chemical and/or enzymatic modifications of the analyte molecule(s) performed in situ. [0048]
  • Another object is to provide sample presenting surfaces in a variety of sizes and configurations (up to 4“×4”) with multiple (up to 10,000 or more) spots (including spots down to <0.001 inch diameter) of affinity reagents arranged in predetermined arrays for the selective adsorption of numerous different analytes (e.g., clinical chemical marker proteins) to enable a wide spectrum sampling of the macromolecular composition of biological samples/fluids. [0049]
  • As shown more fully below, the present invention overcomes limitations and disabilities of the prior art by providing probe tips or sample plates whose surfaces have been derivatized with biospecific affinity reagents which will selectively bind specific groups or types of biomolecules or other analytes out of an undifferentiated sample (such as blood or urine). Appropriate selection of the affinity reagents used to derivatize the probe tip surface therefore makes possible the selection from the undifferentiated sample and binding to the probe tip of the specific types or groups of biological or other macromolecules under investigation, or subsequent examination (e.g., quantification and/or structure elucidation) by mass spectrometry. This has the advantage of achieving both the purification of the analyte sample previously required and the effect of concentrating the analyte. It reduces by a factor of 1,000 to 100,000 the amount of analyte needed for the mass spectrometry examination, since only the macromolecules which attach to the biospecific affinity reagents are removed from the analyte sample, and these can be sequestered on predetermined areas of the probe tips or sample plates that are even less than the laser spot size. [0050]
  • It also has been found that the probe tips used in the process of the invention need not be metal or metal-coated, as with prior art procedures. Research involved in the invention has involved glass and synthetic polymer surfaces such as polystyrene, polypropylene, polyethylene, polycarbonate and other polymers including biopolymers, for the probe tips which have been covalently or noncovalently derivatized for immobilization of specific reagents that will direct the selective adsorption of specific analytes. These surfaces will include immobilized metal ions, immobilized proteins, peptides, enzymes, and inhibitor molecules, immobilized DNA and RNA, immobilized antibodies, immobilized reducing agents, immobilized carbohydrates and lectins, immobilized dyes and immobilized protein surface domains involved in molecular recognition (e.g., dimerization domains and subunits). Some of the chemical and surface structures are as yet unknowvn. [0051]
  • The preferred probe tip, or sample plate, for selective adsorption/presentation of sample for mass analysis are (1) stainless steel (or other metal) with a synthetic polymer coating (e.g., cross-linked dextran or agarose, nylon, polyethylene, polystyrene) suitable for covalent attachment of specific biomolecules or other nonbiological affinity reagents, (2) glass or ceramic, and/or (3) plastic (synthetic polymer). The chemical structures involved in the selective immobilization of affinity reagents to these probe surfaces will encompass the known variety of oxygen-dependent, carbon-dependent, sulfur-dependent, and/or nitrogen-dependent means of covalent or noncovalent immobilization. The methods and chemical reactions used in producing such surfaces derivatized with biospecific affinity reagents already are known by those skilled in the art. Two features of the invention, however, are (1) the specific size and localization of the derivatized surface with respect to the laser beam and (2) the affinity directed presentation of specific analyte molecules (e.g., macromolecule or biopolymer) at a defined surface density or local concentration required for the efficient detection by laser desorption/ionization time-of-flight mass spectrometry. This can be accomplished by arranging the affinity adsorption “spots” (0.005 to 0.080 inch diameter) on the probe surface in a defined manner (400 to 1,000 spots could be placed on a surface about the size of a glass slide). [0052]
  • An additional discovery involves the fact that pH modified chemical matrices can be used on these surfaces to facilitate desorption/ionization without disruption of conditions necessary for subsequent sample modification. As discussed above, prior art matrix materials used for biomolecular mass spectrometry are acidic. The exact chemical structure of the pH-modified matrices still are unknown. However, by suitable neutralization of the matrix material, it can be made largely passive to subsequent chemical or enzymatic reactions carried out on the analyte molecules presented on the derivatized probe tip surface by the biospecific affinity reagents. This makes possible the carrying out of chemical reactions on the analyte molecules presented on the probe tips. Since only a small fraction of the analyte molecules are used in each desorption/mass spectrometer measurement, a number of sequential chemical and/or enzymatic modifications of the samples, in situ, on the probe tips, and subsequent analysis of the modified samples by mass spectrometry, can be carried out on the same probe tips in order to more accurately determine exactly what molecule is present, or other characteristics or information about the molecule, including its structure. [0053]
  • Finally, even when these matrix molecules are immobilized on a probe tip surface, the analyte deposited on such a surface can be desorbed with a laser beam. This circumvents the contamination of the analyte by the matrix molecules. As a particular feature of the invention, we have shown that some energy absorbing molecules that do not work as “matrix” molecules when added to analytes as a solution of free molecules (as in prior art) do indeed work well to facilitate the desorption of intact analyte molecules after being immobilized. [0054]
  • It seems likely that these improvements in the procedure will enable bioanalytical and medical instrument manufacturers to develop a machine for the automated evaluation of a single protein sample deposited on a surface and modified with numerous chemical and/or enzymatic reactions performed in situ.[0055]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The foregoing and other objects and advantages of the invention will be apparent from the following specification and from the accompanying drawings. [0056]
  • FIG. 1A is a mass spectrum of peptide mixtures using sinapinic acid pH 6.5 as the matrix. FIG. 1B is a mass spectrum of the same peptide mixtures after in situ addition of CuSO[0057] 4.
  • FIG. 2A is a mass spectrum of human casein phosphopeptide (R1-K18+5P) using sinapinic acid pH 6.5 as the matrix. FIG. 2B shows the mass spectrum of the same peptide after in situ alkaline phosphatase digestion for 5 and 10 min respectively. FIG. 2D shows the mass spectrum of the same peptide using dihydroxybenzoic acid pH 2 as the matrix, after in situ alkaline phosphatase digestion for 10 min. [0058]
  • FIG. 3 is a mass spectrum histidine-rich glycoprotein (GHHPH)[0059] 5G peptide using sinapinic acid pH 6.2 as the matrix before and after in situ digestion with carboxypeptidase P.
  • FIG. 4 is a composite mass spectra of peptide mixtures using sinapinic acid as the matrix on glass, polypropylene-coated steel, polystyrene-coated steel and nylon probe tips. [0060]
  • FIG. 5A is a mass spectrum of peptides unadsorbed by TSK SW-IDA-Cu(II). FIG. 5B is a mass spectrum of peptide adsorbed by TSK SW-IDA-Cu(II). FIG. 5C is a mass spectrum of the same peptide adsorbed on TSK SW-IDA-Cu(II) after water wash. [0061]
  • FIG. 6 is a mass spectrum of myoglobin (<8 fmole) affinity-adsorbed on TSK SW-IDA-Cu(II). [0062]
  • FIG. 7A is a mass spectrum of proteins/peptides in infant formula. FIG. 7B is a mass spectrum of phosphopeptides in the same sample affinity-adsorbed on Sepharose-TED-Fe(III). FIG. 7C is a mass spectrum of proteins/peptides in gastric aspirate of preterm infant. FIG. 7D is a mass spectrum of the phosphopeptides in the same sample adsorbed on Sepharose-TED-Fe(III). [0063]
  • FIG. 8 (bottom) is a mass spectrum of rabbit anti-human lactoferrin immunoglobin affinity adsorbed on paramagnetic Dynabead-sheep anti-rabbit IgG. FIG. 8 (top) is a mass spectrum of human lactoferrin and rabbit anti-human lactoferrin IgG complex affinity adsorbed on paramagmetic Dynabead-sheep anti-rabbit IgG. [0064]
  • FIG. 9 is a mass spectrum of human lactoferrin affinity adsorbed on a single bead of agarose-single-stranded DNA deposited on a 0.5 mm diameter steel probe tip. [0065]
  • FIG. 10 is the mass spectrum of human lactoferrin affinity adsorbed from urine on agarose-single-stranded DNA. [0066]
  • FIG. 11A is a mass spectrum of human gastrointestinal fluid. FIG. 11B is a mass spectrum of trypsin in the same sample affinity adsorbed on AffiGel 10-soybean trypsin inhibitor. [0067]
  • FIG. 12A is a mass spectrum of human serum proteins. FIG. 12B is a mass spectrum of human serum albumin in the same sample affinity adsorbed on agarose-Cibacron blue. [0068]
  • FIG. 13 is a drawing of the surface bound cinnamamide; R represents the surface plus cross-linear. [0069]
  • FIG. 14A is a mass spectrum of peptide mixtures on surface bound cinnamamide. FIG. 14B shows the mass spectrum of the same peptide mixtures on free cinnamamide. [0070]
  • FIG. 15 is a drawing of the surface bound cinnamyl bromide; tvo structural forms are possible; R represents the surface plus cross-linear. [0071]
  • FIG. 16A is a mass spectrum of peptide mixtures on surface bound cinnamyl bromide. FIG. 16B is a mass spectrum of the same peptide mixtures on free cinnamyl bromide. [0072]
  • FIG. 17 is a drawing of the surface bound MAP-dihydroxybenzoic acid; R represents the surface plus cross-linear. [0073]
  • FIG. 18 is a mass spectrum of peptide mixtures on surface bound MAP alone (control surface). FIG. 18B is a mass spectrum of the same peptide mixtures on surface bound MAP-dihydroxybenzoic acid. [0074]
  • FIG. 19A is a mass spectrum of myoglobin on surface bound cyanohydroxycinnamic acid. FIG. 19B is the same mass spectrum in the low mass region.[0075]
  • DESCRIPTION OF THE PREFERRED EMBODIMENTS Detailed Description
  • Usage of Conventional Matrix in Aqueous, pH-neutralized Form [0076]
  • EXAMPLES
  • Sinapinic acid (dimethoxy hydroxycinnamic acid) (Aldrich Chemical Co., Inc., Milwaukee, Wis.) 20 mg/ml water suspension (intrinsic pH 3.88) Dihydoxybenzoic acid (Aldrich) 20 mg/ml water (intrinsic pH 2.07) Cyanohydroxycinnamic acid (Aldrich) 20 mg/ml water suspension (intrinsic pH 3.3) each titrated with triethylamine (Pierce, Rockford, Ill.) to pH 6.5, 7.2 and 6.5 respectively [0077]
  • 2 ul of the matrix solution was mixed with 1 ul of sample and allowed to air dry[0078]
  • 1. A mixture of synthetic peptides-human histidine-rich glycoprotein peptide (GHHPH)[0079] 2G, (GHHPH)5G, human estrogen receptor dimerization domain (D473-L525) with neutralized sinapinic acid as the matrix, in the absence and presence of Cu(II). FIG. 1 showed the in situ metal-binding properties of the peptides under neutralized condition.
  • 2. Casein phosphopeptide (R1-K18+5P) with sinapinic acid pH 6.5. Followed by in situ alkaline phosphatase (0.5 ul, Sigma) digestion for 10 min at room temperature. Similar in situ digestion on the same peptide with dihydoxybenzoic acid (prepared in 30% methanol/0.1% trifluoroacetic acid) was used as control. FIG. 2 showed the more efficient enzymatic dephosphorylation under neutralized condition. [0080]
  • 3. Mixture of synthetic peptides as in 1 with sinapinic acid pH 6.2, followed by in situ carboxypeptidase P (1 ul, Boehringer Mannheim Corp, Indianapolis, Id., 20 ug/50 ul) digestion for 30 min at room temperature. FIG. 3 showed preferential removal of C-terminal amino acid from histidine-rich glycoprotein peptide. Also showed unambiguous C-terminal determination even in peptide mixtures.[0081]
  • Usage of Probe Tip (Surface) Materials (Composition) other than Stainless Steel or Platinum for Sample Deposition [0082]
  • EXAMPLES
  • Molten polypropylene or polystyrene was deposited on stainless steel probe tip so as to cover it completely [0083]
  • Solid glass rod (1.5 mm dia) was cut into 1 cm segments and inserted into stainless steel probe tip support [0084]
  • Solid nylon (Trimmer line, 1.5 mm dia, Arnold, Shelby, Ohio) was cut into 1 cm segments and inserted into stainless steel probe tip support [0085]
  • Magnetic stir. bars (1.5×8 mm, teflon coated, Curtin Matheson Scientific, Inc., Houston Tex.) inserted into stainless steel probe tip support [0086]
  • Peptide mixtures (as in FIG. 1 with dihydroxybenzoic acid in 30% methanol/0.1% TFA) on all four surfaces. FIG. 4 [0087]
  • Affinity-directed Laser Desorption (with Matrix Added as Described in Prior Art) [0088]
  • EXAMPLES
  • [0089] Group 1. Immobilized Metal Ion as the Affinity Ligand
  • Cu(II) was chelated by iminodiacetate group covalently attached to either porous agarose beads (Chelating Sepharose Fast Flow, Pharmacia Biotech Inc., Piscataway, N.J., ligand density 22-30 umole/ml gel) or solid TSK-SW beads (ToyoSoda, Japan, [0090] ligand density 20 umole/ml gel)
  • Fe(III) was chelated by tris(carboxymethyl)ethylenediamine-Sepharose 6B (synthesized as described by Yip and Hutchens, Protein Expression and Purification 2(1991)355-362, ligand density 65 umole/ml)[0091]
  • 1. A mixture of synthetic peptides, neurotensin (30 nmole), sperm activating peptide (50 nmole) and angiotensin I (150 nmole), were mixed with 50 ul packed volume of TSK SW-IDA-Cu(II) at pH 7.0 (20 mM sodium phosphate, 0.5 M NaCI) at room temperature for 10 min. The gel was then washed with 3×200 ul sodium phosphate buffer, containing 0.5 M NaCl, pH 7.0 and suspended in equal volume of water. 2 ul of the gel suspension was mixed with 1 ul sinapinic acid (methanol). FIG. 5A showed the molecular ions (and multiple Na-adducts) of neurotensin and sperm activating factor which were not adsorbed by the IDA-Cu(II). The mass spectrum in FIG. 5B showed mainly the angiotensin I plus Na-adducts. When the IDA-Cu(II) gel was further washed with 500 ul of water 2×, the resulting mass spectrum showed only the parent angiotensin I species with no other adduct peaks. When the IDA-Cu(II) gel beads with adsorbed angiotensin was incubated with cyanohydroxycinnamic acid (20 mg/ml water) pH 7.0 for 10 min at room temperature and then analyzed separately, the angiotensin I was found to be still associated with the gel beads and not with the matrix solution. [0092]
  • 2. Horse heart myoglobin (325 pmole) was mixed with 50 ul of TSK SW-IDA-Cu(II) gel beads in 20 mM sodium phosphate, 0.5 M NaCl, pH 7.0 at room temperature for 10 min. The gel beads were then washed with 2×500 ul of buffer and 2×500 ul of water. The beads were suspended in equal volume of water and then serial diluted into water. 0.5 ul of the diluted gel suspension was mixed with 1 ul of sinapinic acid (30% methanol/0.1% TFA). A detectable signal (after averaging 50 laser shots) of myoglobin was still obtained when the calculated quantity equivalent to or less than 8 fmole was deposited on the probe tip. FIG. 6 [0093]
  • 3. 100 ul of infant formula and gastric content of preterm infant aspirated 90 min after feeding of infant formula was mixed with 50 ul of TED-Fe(III) in 0.1 M MES, 0.15 M NaCl, pH 6.5 at room temperature for 15 min. The gel beads were then washed with 3×500 ul of MES buffer and then with 1×500 ul of water. 1 ul of the gel suspension was mixed with 2 ul of sinapinic acid (50% acetonitrile/0.1% TFA). The result showed that gastric aspirate had much more low molecular weight phosphopeptides (i.e., bound by TED-Fe(III)) than the formula due to proteolytic digestion. In situ alkaline phosphatase digestion of peptides adsorbed on the TED-Fe(III) gel beads showed shifts to lower molecular weight indicating that they are indeed phosphopeptides. FIG. 7 [0094]
  • Group 2. Immobilized Antibody as the Affinity Ligand [0095]
  • Polyclonal rabbit anti-human lactoferrin antibody was custom generated for this lab by Bethyl Laboratories (Montgomery, Tex.). It was purified by thiophilic adsorption and then by immobilized lactoferrin column. Sheep anti-rabbit IgG covalently attached to magnetic beads were obtained from Dynal AS (Oslo, Norway) (uniform 2.8 um superparamagnetic polystyrene beads, [0096] ligand density 10 ug sheep IgG per mg bead).
  • 1. Human lactoferrin (1 nmole) was incubated with rabbit antihuman lactoferrin at 37° for 30 min. Subsequently, 40 ul of sheep anti-rabbit IgG on Dynabeads (6-7×10[0097] 8 beads/ml) was added and incubated at 37° for 30 min. The beads were then washed with 3×500 ul of sodium phosphate buffer, and 2×500 ul of water. The final amount of human lactoferrin bound to the complex was estimated to be 4 pmole. Approximately {fraction (1/10 )} of the beads was transferred to a magnetic probe tip and mixed with 2 ul of sinapinic acid (30% MeOH/0.1% TFA). Result showed the lactoferrin ion signal in addition to the rabbit IgG signal. FIG. 8
  • [0098] Group 3. Immobilized Nucleic Acid as the Affinity Ligand
  • Single-strand DNA immobilized on 4% agarose beads was obtained from GIBCO BRL, Gaithersburg, Md. The ligand density was 0.5-1.0 mg/ml.[0099]
  • 1. 200 ul of [0100] 125I human lactoferrin (equivalent to 49 nmole) was mixed with 100 ul of immobilized single-strand DNA in 20 mM HEPES, pH 7.0 at room temperature for 10 min. The beads were then washed with 5×500 ul of HEPES buffer and then suspended in equal volume of water. The amount of lactoferrin bound per bead was found to be 62 fmole by determining the radioactivity and counting the number of beads per unit volume. Various numbers of beads (from 1 to 12) were deposited on 0.5 mm diameter probe tips and mixed with 0.2 ul of sinapinic acid (30% methanol/0.1% TFA). Lactoferrin ion signals were obtained with multiple 100 laser shots on a single bead with adsorbed lactoferrin. FIG. 9
  • 2. 30 pmole of [0101] 59Fe-human lactoferrin was added to 1 ml of preterm infant urine and mixed with 20 ul of immobilized single-strand DNA on agarose in 0.1 M HEPES pH 7.4 at room temperature for 15 min. The beads were washed with 2×500 ul HEPES buffer, and 2×500 ul of water. The beads were then suspended in equal volume of water and 1 ul (equivalent to not more than 350 fmole as determined by radioactivity) was mixed with 1 ul sinapinic acid (30% methanol/0.1% TFA) on a probe tip. Positive lactoferrin signals were obtained for multiple 50 laser shots. FIG. 10
  • Group 4. Immobilized Biomolecule as the Affinity Ligand Soybean trypsin inhibitor (Sigma, St Louis, Mo.) was immobilized on AffiGel 10 (BioRad Laboratories, Hercules, Calif., ligand density 15 umole/ml) according to manufacturer's instructions.[0102]
  • 1. [0103] 100 ul of human gastrointestinal aspirate was mixed with 50 ul of immobilized soybean trypsin inhibitor in 20 mM sodium phosphate, 0.5 M sodium chloride, pH 7, at room temperature for 15 min. The gel beads were then washed with 3×500 ul of phosphate buffer, and 2×500 ul of water. 1 ul of gel bead suspension was mixed with 2 ul of sinapinic acid (50% acetonitrile/0.1% TFA). Result showed the presence of trypsin and trypsinogen in the aspirate. FIG. 11
  • [0104] Group 5. Immobilized Dye as the Affinity Ligand
  • Cibacron Blue 3GA-agarose ([0105] Type 3000, 4% beaded agarose, ligand density 2-5 umoles/ml, Sigma).
  • Other immobilized dyes include Reactive Red 120-agarose, Reactive Blue-agarose, Reactive Green-agarose, Reactive Yellow-agarose (Sigma)[0106]
  • 1. 200 ul of human plasma was mixed with 50 ul of immobilized dye in 20 mM sodium phosphate, 0.5 M NaCl, pH 7.0 at room temperature for 10 min. The gel beads were then washed with 3×500 ul of phosphate buffer and 2×500 ul of water. 1 ul of gel bead suspension was mixed with 2 ul of sinapinic acid (50% acetonitrile/0.1% TFA). Result showed the selective adsorption of human serum albumin from the serum sample by Cibacron Blue. FIG. 12 [0107]
  • Surface-enhanced Laser Desorption [0108]
  • EXAMPLES
  • [0109] Group 1. Energy-absorbing Molecule Covalently Bonded to Surface via the N-group
  • Cinnamamide (Aldrich, not a matrix by prior art) was dissolved in isopropanol/0.5 M sodium carbonate (3:1) and mixed with divinyl sulfone (Fluka, Ronkonkoma, N.Y.) activated Sepharose (Pharmacia) at room temperature for 2 hr. The excess molecules were washed away with isopropanol. The proposed structure was presented in FIG. 13. 2 ul of bound or free molecule was deposited on the probe tips, 1 ul of peptide mixtures in 0.1% TFA was added on top and the result showed the peptide ion signals detected only for the bound form. FIG. 14. [0110]
  • Group 2. Energy Absorbing Molecule Covalently Bonded to Surface via the C-group [0111]
  • Cynnamyl bromide (Aldrich, not a matrix by prior art) was dissolved in isopropanol/0.5 M sodium carbonate and mixed with divinyl sulfone-activated Sepharose at room temperature overnight. The excess molecules were washed away with isopropanol. The proposed structures are presented in FIG. 15. 2 ul of the bound or free molecule was deposited on the probe tip, 1 ul of peptide mixtures in 0.1% TFA was added on top and the result showed the detection of peptide ion signal only for the bound form. FIG. 16. [0112]
  • [0113] Group 3. Energy Absorbing Molecule Covalently Bonded to Surface via the C-group
  • Dihydroxybenzoic acid was activated by carbodiimide and mixed with Fmoc-[0114] MAP 8 branch resin (Applied Biosystems, Forster City, Calif.) overnight. The proposed structure was presented in FIG. 17. After washing, 1 ul of the bonded molecule on MAP or the MAP alone in 50% acetonitrile/0.1% TFA were deposited on the probe tip, 1 ul of peptide mixture was added on top, the resulting mass spectrum was presented in FIG. 21.
  • Group 4. Energy Absorbing Molecule Covalently Bonded to Surface via Undetermined Group. [0115]
  • Cyanohydroxycinnamic acid was dissolved in methanol and mixed with AffiGel 10 (BioRad) at room temperature for two hours. The unbound molecules were washed away with methanol. Protein samples that are found to desorb successfully from this modified surface include myoglobin (FIG. 19), trypsin and carbonic anhydrase. [0116]
  • These examples (Groups 1-4) are also demonstrations of combined surface-enhanced and affinity-directed desorption where the adsorbed (bonded) energy absorbing molecular also act as affinity adsorption reagents to enhance the capture of analyte molecules. [0117]
  • Definitions[0118]
  • (1) “Presenting surface”—the probe tip, sample plate or other surface on which the analyte and matrix are presented for desorption/ionization and analysis for example by mass spectrometry. [0119]
  • (2) “Matrix”—as described in prior art as the substance mixed with the analyte (typically prior to deposition) and deposited on the presenting surface in association with the analyte to absorb at least part of the energy from the energy source (e.g., laser) to facilitate desorption of intact molecules of the analyte. [0120]
  • (3) “Analyte”—the material which is the subject of desorption and investigation by mass spectrometry or other means for detection. [0121]
  • (4) “Affinity reagent” (analyte capture device)—the class of molecules (both man made, unnatural, natural and biological) and/or compounds which have the ability of being retained on the presenting surface (by covalent bonding, chemical absorption, etc.) while retaining the ability of recognition and bonding to an analyte. [0122]
  • (5) “Desorption”—the departure of analyte from the surface and/or the entry of the analyte into a gaseous phase. [0123]
  • (6) “Ionization”—the process of creating or retaining on an analyte an electrical charge equal to plus or minus one or more electron units. [0124]
  • (7) “Adduct”—the appearance of an additional mass associated with the analyte and usually caused by the reaction of excess matrix (or matrix break-down products) directly with the analyte. [0125]
  • (8) “Adsorption”—the chemical bonding (covalent and/or noncovalent) of the energy-absorbing molecules, the affinity reagent (i.e., analyte capture device), and/or the analyte to the probe (presenting surface).[0126]

Claims (31)

What is claimed:
1. An apparatus for measuring the mass of analyte molecules by means of mass spectrometry, said apparatus comprising:
a spectrometer tube;
vacuum means for applying a vacuum to the interior of said tube;
electrical potential means within the tube for applying an accelerating electrical potential to desorbed analyte molecules;
sample presenting means removably insertable into said spectrometer means, for presenting said analyte molecules in association with a matrix material for promoting desorption and ionization of said analyte molecules, said sample presenting means being adapted to present said analyte molecules on or above the surface of said matrix material, whereby at least a portion of said analyte molecules not consumed in said mass spectrometry analysis will remain accessible for subsequent chemical analytical procedures;
laser beam means for producing a laser beam directed to said analyte molecules and matrix material on said sample presenting means inserted into said spectrometer means, for imparting sufficient energy to desorb and ionize a portion of said analyte molecules on said sample presenting means; and
detector means associated with said spectrometer tube for detecting the impact of accelerated ionized analyte molecules thereon.
2. A method in mass spectrometry to measure the mass of an analyte molecule, said method comprising the steps of:
derivitizing a surface on a probe tip face with an affinity reagent having means for selectively bonding with an analyte molecule;
exposing said derivitized probe tip face to a source of said analyte molecule so as to bond said analyte molecule thereto;
placing the probe tip into one end of a time-of-flight mass spectrometer and applying a vacuum and an electric field to form an accelerating potential within the spectrometer;
striking the probe tip face within the spectrometer with a series of laser pulses in order to desorb ions of said analyte molecules from said tip;
detecting the mass weights of the ions by their time of flight within said mass spectrometer; and
displaying such detected mass weights.
3. The method according to claim 2 comprising additionally applying a desorption assisting matrix material to said probe tip face in association with said affinity reagent, said matrix material being applied in a manner so as not to interfere with said means on said affinity reagent for selectively bonding with said analyte molecules,
a portion of said analyte molecules which are not desorbed from said probe tip remaining chemically accessible for subsequent analytical procedures without the necessity for separating them from said matrix material.
4. The method according to claim 3 comprising additionally,
removing said probe tip from said mass spectrometer;
performing a chemical procedure on said portion of said analyte molecules so as to alter the chemical composition of said portion of said analyte molecules;
reinserting said probe tip with said chemically altered analyte molecules thereon; and
performing a subsequent mass spectrometry analysis to determine the molecular weight of said chemically altered analyte molecules.
5. The method according to claim 2 wherein said affinity reagent is chemically bonded to said face of said probe tip.
6. The method according to claim 2 wherein said affinity reagent is physically adhered to said face of said probe tip.
7. The method according to claim 2 wherein said affinity reagent is adapted to chemically bond to said analyte molecules.
8. The method according to claim 2 wherein said affinity reagent is adapted to biologically adhere to said analyte molecules.
9. The method according to claim 2 wherein said analyte molecules are biomolecules and said affinity reagent is adapted to selectively isolate said biomolecules from an undifferentiated biological sample.
10. The method according to claim 3 wherein said matrix materials are in the weakly acidic to strongly basic pH range.
11. The method according to claim 3 wherein said matrix materials have a pH above 6.0.
12. The method according to claim 2 wherein said face of said probe tip is formed of an electrically insulating material.
13. A method of measuring the mass of analyte molecules by means of laser desorption/ionization, time-of-flight mass spectrometry in which a matrix material is used in conjunction with said analyte molecules for facilitating desorption and ionization of the analyte molecules, the improvement comprising:
presenting the analyte molecules on or above the surface of the matrix material, whereby at least a portion of the analyte molecules not desorbed in said mass spectrometry analysis remain chemically accessible for subsequent analytical procedures, in situ, on said probe tip, without the necessity for separating said portion of said analyte molecules from said matrix material.
14. An apparatus for facilitating desorption and ionization of analyte molecules for analysis by mass spectrometry, said apparatus comprising:
a substrate; and
an affinity reagent attached to said substrate and having means for selectively bonding with said analyte molecules.
15. The apparatus according to claim 14 wherein said substrate comprises the surface of a probe tip for use in a time-of-flight mass spectrometry analyzer.
16. The apparatus according to claim 14 wherein said affinity reagent is chemically bonded to said substrate.
17. The apparatus according to claim 14 wherein said affinity reagent is physically adhered to said substrate.
18. The apparatus according to claim 14 wherein said affinity reagent is adapted to chemically bond to said analyte molecules.
19. The apparatus according to claim 14 wherein said affinity reagent is adapted to biologically adhere to said analyte molecules.
20. The apparatus according to claim 14 wherein said analyte molecules are biomolecules and said affinity reagent is adapted to selectively isolate said biomolecules from an undifferentiated biological sample.
21. The apparatus according to claim 14 comprising additionally a matrix material deposited on said substrate in association with said affinity reagent in a manner so as to not render ineffective said means on said affinity reagents for selective bonding with said analyte molecules.
22. The apparatus according to claim 21 wherein said matrix material is in the weakly acidic to strongly basic pH range.
23. The apparatus according to claim 21 wherein said matrix material has a pH above 6.0.
24. The apparatus according to claim 14 wherein said substrate is formed of an electrically insulating material.
25. A method for preparing a surface for presenting analyte molecules for analysis by time-of-flight mass spectrometry, said method comprising:
providing a substrate on said surface for supporting said analyte;
derivitizing said substrate with an affinity reagent having means for selectively bonding with said analyte; and
depositing a desorption/ionization promoting matrix material on said substrate in association with said affinity reagent, said matrix material being deposited in a manner so as to not render ineffective said means on said affinity reagent for selectively bonding with said analyte.
26. A method for preparing a surface for presenting analyte molecules for analysis, said method comprising:
providing a substrate on said surface for supporting said analyte;
derivitizing said substrate with an affinity reagent having means for selectively bonding with said analyte; and
a means for detection of said analyte molecules bonded with said affinity reagent.
27. The method according to claim 26 comprising additionally the step of applying a detection material to said surface.
28. The method according to claim 27 wherein such detection material comprises a fluorescing species.
29. The method according to claim 27 wherein such detection material comprises an enzymatic species.
30. The method according to claim 27 comprising additionally wherein such detection material comprises a radioactive species.
31. The method according to claim 27 comprising additionally wherein such detection material comprises a light-emitting species.
US10/728,442 1993-05-28 2003-12-05 Method and apparatus for desorption and ionization of analytes Abandoned US20040191922A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/728,442 US20040191922A1 (en) 1993-05-28 2003-12-05 Method and apparatus for desorption and ionization of analytes
US11/347,495 US7449150B2 (en) 1993-05-28 2006-02-03 Probe and apparatus for desorption and ionization of analytes

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6889693A 1993-05-28 1993-05-28
US09/809,657 US6734022B2 (en) 1993-05-28 2001-03-15 Method and apparatus for desorption and ionization of analytes
US10/728,442 US20040191922A1 (en) 1993-05-28 2003-12-05 Method and apparatus for desorption and ionization of analytes

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/809,657 Continuation US6734022B2 (en) 1993-05-28 2001-03-15 Method and apparatus for desorption and ionization of analytes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/347,495 Continuation US7449150B2 (en) 1993-05-28 2006-02-03 Probe and apparatus for desorption and ionization of analytes

Publications (1)

Publication Number Publication Date
US20040191922A1 true US20040191922A1 (en) 2004-09-30

Family

ID=22085400

Family Applications (9)

Application Number Title Priority Date Filing Date
US08/483,357 Expired - Lifetime US5719060A (en) 1993-05-28 1995-06-07 Method and apparatus for desorption and ionization of analytes
US08/785,636 Expired - Lifetime US6027942A (en) 1993-05-28 1997-01-17 Surface-enhanced affinity capture for desorption and detection or analytes
US08/785,637 Expired - Fee Related US5894063A (en) 1993-05-28 1997-01-17 Surface-enhanced neat desorption for disorption and detection of analytes
US09/095,407 Expired - Lifetime US6124137A (en) 1993-05-28 1998-06-10 Surface-enhanced photolabile attachment and release for desorption and detection of analytes
US09/123,253 Expired - Fee Related US7071003B2 (en) 1993-05-28 1998-07-27 Surface-enhanced laser desorption/Ionization for desorption and detection of analytes
US09/742,494 Expired - Lifetime US6528320B2 (en) 1993-05-28 2000-12-20 Method and apparatus for desorption and ionization of analytes
US09/809,657 Expired - Fee Related US6734022B2 (en) 1993-05-28 2001-03-15 Method and apparatus for desorption and ionization of analytes
US10/728,442 Abandoned US20040191922A1 (en) 1993-05-28 2003-12-05 Method and apparatus for desorption and ionization of analytes
US11/347,495 Expired - Fee Related US7449150B2 (en) 1993-05-28 2006-02-03 Probe and apparatus for desorption and ionization of analytes

Family Applications Before (7)

Application Number Title Priority Date Filing Date
US08/483,357 Expired - Lifetime US5719060A (en) 1993-05-28 1995-06-07 Method and apparatus for desorption and ionization of analytes
US08/785,636 Expired - Lifetime US6027942A (en) 1993-05-28 1997-01-17 Surface-enhanced affinity capture for desorption and detection or analytes
US08/785,637 Expired - Fee Related US5894063A (en) 1993-05-28 1997-01-17 Surface-enhanced neat desorption for disorption and detection of analytes
US09/095,407 Expired - Lifetime US6124137A (en) 1993-05-28 1998-06-10 Surface-enhanced photolabile attachment and release for desorption and detection of analytes
US09/123,253 Expired - Fee Related US7071003B2 (en) 1993-05-28 1998-07-27 Surface-enhanced laser desorption/Ionization for desorption and detection of analytes
US09/742,494 Expired - Lifetime US6528320B2 (en) 1993-05-28 2000-12-20 Method and apparatus for desorption and ionization of analytes
US09/809,657 Expired - Fee Related US6734022B2 (en) 1993-05-28 2001-03-15 Method and apparatus for desorption and ionization of analytes

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/347,495 Expired - Fee Related US7449150B2 (en) 1993-05-28 2006-02-03 Probe and apparatus for desorption and ionization of analytes

Country Status (12)

Country Link
US (9) US5719060A (en)
EP (2) EP1347493A3 (en)
JP (3) JP3639594B2 (en)
AT (1) ATE242485T1 (en)
AU (1) AU676582B2 (en)
CA (2) CA2512290C (en)
DE (1) DE69432791T2 (en)
DK (1) DK0700521T3 (en)
ES (1) ES2201077T3 (en)
NZ (1) NZ267842A (en)
PT (1) PT700521E (en)
WO (1) WO1994028418A1 (en)

Families Citing this family (421)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0664884A4 (en) * 1992-05-29 1997-05-02 Univ Rockefeller Method and product for the sequence determination of peptides using a mass spectrometer.
US6436635B1 (en) * 1992-11-06 2002-08-20 Boston University Solid phase sequencing of double-stranded nucleic acids
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US20020037517A1 (en) * 1993-05-28 2002-03-28 Hutchens T. William Methods for sequencing biopolymers
CA2512290C (en) * 1993-05-28 2010-02-02 Baylor College Of Medicine Method and apparatus for desorption and ionization of analytes
US6071610A (en) * 1993-11-12 2000-06-06 Waters Investments Limited Enhanced resolution matrix-laser desorption and ionization TOF-MS sample surface
US7803529B1 (en) 1995-04-11 2010-09-28 Sequenom, Inc. Solid phase sequencing of biopolymers
US20060063193A1 (en) * 1995-04-11 2006-03-23 Dong-Jing Fu Solid phase sequencing of double-stranded nucleic acids
US20020164818A1 (en) * 1995-05-23 2002-11-07 Gruber Karl F. Mass spectrometric immunoassay analysis of specific proteins and variants present in various biological fluids
US20030027216A1 (en) * 2001-07-02 2003-02-06 Kiernan Urban A. Analysis of proteins from biological fluids using mass spectrometric immunoassay
WO1996037777A1 (en) 1995-05-23 1996-11-28 Nelson Randall W Mass spectrometric immunoassay
US6004770A (en) * 1995-06-07 1999-12-21 Arizona State University Board Of Regents Sample presentation apparatus for mass spectrometry
CA2221250C (en) * 1995-06-07 2007-11-20 Arizona Board Of Regents A sample presentation apparatus for mass spectrometry
AU756020B2 (en) * 1995-06-07 2003-01-02 Arizona Board Of Regents, The A sample presentation apparatus for mass spectrometry
US6316266B1 (en) 1995-06-07 2001-11-13 Arizona State University Board Of Regents Sample presentation apparatus for mass spectrometry
US6093541A (en) * 1995-06-07 2000-07-25 Arizona State University Board Of Regents Mass spectrometer having a derivatized sample presentation apparatus
GB9518429D0 (en) * 1995-09-08 1995-11-08 Pharmacia Biosensor A rapid method for providing kinetic and structural data in molecular interaction analysis
WO1997012989A1 (en) 1995-10-02 1997-04-10 Katoot Mohammad W Biologically-active polymers
US5716825A (en) * 1995-11-01 1998-02-10 Hewlett Packard Company Integrated nucleic acid analysis system for MALDI-TOF MS
US5705813A (en) * 1995-11-01 1998-01-06 Hewlett-Packard Company Integrated planar liquid handling system for maldi-TOF MS
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
US6027890A (en) * 1996-01-23 2000-02-22 Rapigene, Inc. Methods and compositions for enhancing sensitivity in the analysis of biological-based assays
US6613508B1 (en) 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
SE9602545L (en) * 1996-06-25 1997-12-26 Michael Mecklenburg Method of discriminating complex biological samples
US7285422B1 (en) * 1997-01-23 2007-10-23 Sequenom, Inc. Systems and methods for preparing and analyzing low volume analyte array elements
US6818394B1 (en) 1996-11-06 2004-11-16 Sequenom, Inc. High density immobilization of nucleic acids
US6024925A (en) 1997-01-23 2000-02-15 Sequenom, Inc. Systems and methods for preparing low volume analyte array elements
EP0881494A1 (en) * 1997-04-29 1998-12-02 Roche Diagnostics GmbH Method of simultaneous determination of proteins and their derivatives
US6451616B1 (en) 1997-05-19 2002-09-17 Robert W. Odom Analysis of molecules bound to solid surfaces using selective bond cleavage processes
AU2002301047B2 (en) * 1997-06-20 2005-11-10 Ciphergen Biosystems, Inc. Retentate Chromatography And Protein Chip Arrays With Applications In Biology And Medicine
EP1387390B1 (en) 1997-06-20 2009-02-18 Bio - Rad Laboratories, Inc. Retentate chromatography and protein chip arrays with applications in biology and medicine
AU2003235062B2 (en) * 1997-06-20 2006-02-02 Ciphergen Biosystems, Inc. Retentate chromatography and protein chip arrays with applications in biology and medicine
NZ516848A (en) * 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US6207370B1 (en) 1997-09-02 2001-03-27 Sequenom, Inc. Diagnostics based on mass spectrometric detection of translated target polypeptides
US5952654A (en) * 1997-10-29 1999-09-14 Northeastern University Field-release mass spectrometry
DE69938623T2 (en) 1998-02-04 2009-05-28 Invitrogen Corp., Carlsbad MICROARRAYS AND ITS USES
US6849847B1 (en) 1998-06-12 2005-02-01 Agilent Technologies, Inc. Ambient pressure matrix-assisted laser desorption ionization (MALDI) apparatus and method of analysis
US6221626B1 (en) 1998-06-30 2001-04-24 University Of Geneva Kit for electroblotting polypeptides separated on an electrophoresis gel
US20020119579A1 (en) * 1998-07-14 2002-08-29 Peter Wagner Arrays devices and methods of use thereof
US6780582B1 (en) * 1998-07-14 2004-08-24 Zyomyx, Inc. Arrays of protein-capture agents and methods of use thereof
US6576478B1 (en) * 1998-07-14 2003-06-10 Zyomyx, Inc. Microdevices for high-throughput screening of biomolecules
US6682942B1 (en) 1998-07-14 2004-01-27 Zyomyx, Inc. Microdevices for screening biomolecules
US6897073B2 (en) * 1998-07-14 2005-05-24 Zyomyx, Inc. Non-specific binding resistant protein arrays and methods for making the same
US6406921B1 (en) * 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6206840B1 (en) * 1998-08-12 2001-03-27 Siemens Aktiengesellschaft Method for the identification of a liquid secreted by a living subject particularly for identification of amniotic fluid
GB9821393D0 (en) * 1998-10-01 1998-11-25 Brax Genomics Ltd Protein profiling 2
US20060172925A1 (en) * 1998-10-26 2006-08-03 Board Of Regents, The University Of Texas System Thio-siRNA aptamers
US20040242521A1 (en) * 1999-10-25 2004-12-02 Board Of Regents, The University Of Texas System Thio-siRNA aptamers
US6423493B1 (en) * 1998-10-26 2002-07-23 Board Of Regents The University Of Texas System Combinatorial selection of oligonucleotide aptamers
AU766334B2 (en) * 1999-01-28 2003-10-16 Universite De Geneve Method and kit for identifying or characterising polypeptides
ATE469699T1 (en) * 1999-02-23 2010-06-15 Caliper Life Sciences Inc MANIPULATION OF MICROPARTICLES IN MICROFLUID SYSTEMS
EP1166329A4 (en) * 1999-03-09 2005-03-23 Scripps Research Inst Improved desorption/ionization of analytes from porous light-absorbing semiconductor
CN1204592C (en) 1999-04-27 2005-06-01 赛弗根生物系统股份有限公司 Probes for gas phase ion spectrometer
CN1169188C (en) 1999-04-29 2004-09-29 赛弗根生物系统股份有限公司 Sample holder with hydrophobic coating for gas phase mass spectrometers
ATE421976T1 (en) 1999-05-18 2009-02-15 Dyax Corp FAB FRAGMENT LIBRARIES AND METHODS FOR USE THEREOF
WO2000077812A2 (en) * 1999-06-10 2000-12-21 Northeastern University Light-induced electron capture at a surface
US20090233806A1 (en) * 1999-07-06 2009-09-17 Carr Francis J Protein isolation and analysis
US7138254B2 (en) 1999-08-02 2006-11-21 Ge Healthcare (Sv) Corp. Methods and apparatus for performing submicroliter reactions with nucleic acids or proteins
AU7331500A (en) 1999-08-27 2001-03-26 Large Scale Proteomics, Corp. Devices for use in maldi mass spectrometry
US6869572B1 (en) * 1999-09-13 2005-03-22 Millipore Corporation High density cast-in-place sample preparation card
JP4014767B2 (en) * 1999-09-17 2007-11-28 富士フイルム株式会社 Rigid macro array
US7167615B1 (en) 1999-11-05 2007-01-23 Board Of Regents, The University Of Texas System Resonant waveguide-grating filters and sensors and methods for making and using same
US6936424B1 (en) 1999-11-16 2005-08-30 Matritech, Inc. Materials and methods for detection and treatment of breast cancer
CA2394942A1 (en) * 1999-12-20 2001-06-28 Stephen J. Fonash Deposited thin films and their use in detection, attachment, and bio-medical applications
US20030087265A1 (en) * 2000-01-21 2003-05-08 Edward Sauter Specific microarrays for breast cancer screening
WO2001062887A1 (en) 2000-02-23 2001-08-30 Zyomyx, Inc. Chips having elevated sample surfaces
US7351540B1 (en) * 2000-03-17 2008-04-01 Merck Patent Gmbh Protein isolation and analysis
CA2301451A1 (en) * 2000-03-20 2001-09-21 Thang T. Pham Method for analysis of analytes by mass spectrometry
US7122790B2 (en) * 2000-05-30 2006-10-17 The Penn State Research Foundation Matrix-free desorption ionization mass spectrometry using tailored morphology layer devices
NZ522859A (en) * 2000-06-19 2005-08-26 Correlogic Systems Inc Heuristic method of classifying objects using a vector space having multiple preclassified data clusters
WO2002004628A2 (en) * 2000-07-06 2002-01-17 Genvec, Inc. Method of identifying a binding partner of a gene product
IL153856A0 (en) * 2000-07-18 2003-07-31 Correlogic Systems Inc A process for discriminating between biological states based on hidden patterns from biological data
ATE282205T1 (en) 2000-07-24 2004-11-15 Health Research Inc METHOD FOR DETECTING PROSTATE-SPECIFIC MEMBRANE ANTIGEN IN SERUM
DE10043042C2 (en) * 2000-09-01 2003-04-17 Bruker Daltonik Gmbh Method for loading a sample carrier with biomolecules for mass spectrometric analysis
JP4706093B2 (en) * 2000-09-25 2011-06-22 富士レビオ株式会社 Method for removing and purifying parvovirus
CA2425434A1 (en) * 2000-10-11 2002-04-18 Tina Morris Methods for characterizing molecular interactions using affinity capture tandem mass spectrometry
US20020142483A1 (en) 2000-10-30 2002-10-03 Sequenom, Inc. Method and apparatus for delivery of submicroliter volumes onto a substrate
US7407773B2 (en) * 2000-11-03 2008-08-05 Procognia, Ltd. Method for characterizing a carbohydrate polymer
US6864065B2 (en) * 2000-11-08 2005-03-08 Surface Logix, Inc. Assays for monitoring cell motility in real-time
US7326563B2 (en) 2000-11-08 2008-02-05 Surface Logix, Inc. Device and method for monitoring leukocyte migration
US7033819B2 (en) 2000-11-08 2006-04-25 Surface Logix, Inc. System for monitoring cell motility in real-time
US7374906B2 (en) 2000-11-08 2008-05-20 Surface Logix, Inc. Biological assays using gradients formed in microfluidic systems
US6893851B2 (en) 2000-11-08 2005-05-17 Surface Logix, Inc. Method for arraying biomolecules and for monitoring cell motility in real-time
US6699665B1 (en) * 2000-11-08 2004-03-02 Surface Logix, Inc. Multiple array system for integrating bioarrays
US6844184B2 (en) * 2000-11-08 2005-01-18 Surface Logix, Inc. Device for arraying biomolecules and for monitoring cell motility in real-time
US7033821B2 (en) * 2000-11-08 2006-04-25 Surface Logix, Inc. Device for monitoring cell motility in real-time
US20030129666A1 (en) * 2001-01-09 2003-07-10 Mitsubishi Pharma Corporation Novel proteome analysis method and devices therefor
JP2002228668A (en) * 2001-01-31 2002-08-14 Shimadzu Corp Automatic sampler
CA2436503A1 (en) * 2001-02-01 2002-08-08 Huw A. Davies Improved methods for protein identification, characterization and sequencing by tandem mass spectrometry
WO2002064621A2 (en) * 2001-02-14 2002-08-22 Attenuon, Llc Histidine proline rich glycoprotein (hprg) as an anti-angiogenic and anti-tumor agent
WO2002071066A1 (en) * 2001-03-02 2002-09-12 Activx Biosciences, Inc. Protein profiling platform
US20030228639A1 (en) * 2001-03-19 2003-12-11 Wright George L Prostate cancer markers
US20030219734A1 (en) * 2001-04-13 2003-11-27 Biosite Incorporated Polypeptides related to natriuretic peptides and methods of their identification and use
US7524635B2 (en) * 2003-04-17 2009-04-28 Biosite Incorporated Methods and compositions for measuring natriuretic peptides and uses thereof
US6804410B2 (en) 2001-04-17 2004-10-12 Large Scale Proteomics Corporation System for optimizing alignment of laser beam with selected points on samples in MALDI mass spectrometer
EP1385998A1 (en) * 2001-04-19 2004-02-04 Ciphergen Biosystems, Inc. Biomolecule characterization using mass spectrometry and affinity tags
US20020155587A1 (en) 2001-04-20 2002-10-24 Sequenom, Inc. System and method for testing a biological sample
WO2002093170A1 (en) * 2001-05-14 2002-11-21 The Penn State Research Foundation Matrix-free desorption ionization mass spectrometry using tailored morphology layer devices
US6825032B2 (en) * 2001-05-14 2004-11-30 Sigma-Aldrich Co. High capacity assay platforms
AU2002305710A1 (en) * 2001-05-25 2002-12-09 Waters Investments Limited Sample concentration maldi plates for maldi mass spectrometry
WO2002096541A1 (en) * 2001-05-25 2002-12-05 Waters Investments Limited Desalting plate for maldi mass spectrometry
JP4264002B2 (en) * 2001-07-17 2009-05-13 バイオ−ラド ラボラトリーズ インコーポレイテッド Latex-based adsorption chip
GB0120131D0 (en) * 2001-08-17 2001-10-10 Micromass Ltd Maldi target plate
EP1421189A2 (en) * 2001-08-22 2004-05-26 Helix Biopharma Corp. Method and device for integrated protein expression, purification and detection
WO2003019193A1 (en) * 2001-08-30 2003-03-06 Ciphergen Biosystems, Inc. Method of diagnosing nephrotic syndrome
US20040043436A1 (en) * 2001-09-21 2004-03-04 Antonia Vlahou Biomarkers of transitional cell carcinoma of the bladder
US7842498B2 (en) 2001-11-08 2010-11-30 Bio-Rad Laboratories, Inc. Hydrophobic surface chip
US20030091976A1 (en) * 2001-11-14 2003-05-15 Ciphergen Biosystems, Inc. Methods for monitoring polypeptide production and purification using surface enhanced laser desorption/ionization mass spectrometry
US20030162190A1 (en) * 2001-11-15 2003-08-28 Gorenstein David G. Phosphoromonothioate and phosphorodithioate oligonucleotide aptamer chip for functional proteomics
US20040018519A1 (en) * 2001-11-16 2004-01-29 Wright ,Jr. George L Methods and devices for quantitative detection of prostate specific membrane antigen and other prostatic markers
US6946653B2 (en) 2001-11-27 2005-09-20 Ciphergen Biosystems, Inc. Methods and apparatus for improved laser desorption ionization tandem mass spectrometry
GB2384778A (en) * 2001-12-21 2003-08-06 Sense Proteomic Ltd Probe for mass spectrometry
US20030207462A1 (en) * 2002-01-25 2003-11-06 Ciphergen Biosystems, Inc. Monomers and polymers having energy absorbing moieties of use in desorption/ionization of analytes
EP1481244A4 (en) * 2002-01-25 2008-07-02 Bio Rad Laboratories Monomers and polymers having energy absorbing moieties of use in desorption/ionization of analytes
WO2003072710A2 (en) * 2002-02-21 2003-09-04 Eastern Virginia Medical School Protein biomarkers that distinguish prostate cancer from non-malignant cells
US20030232396A1 (en) * 2002-02-22 2003-12-18 Biolife Solutions, Inc. Method and use of protein microarray technology and proteomic analysis to determine efficacy of human and xenographic cell, tissue and organ transplant
US20090149335A1 (en) * 2002-02-22 2009-06-11 Biolife Solutions Inc. Method and use of microarray technology and proteogenomic analysis to predict efficacy of human and xenographic cell, tissue and organ transplant
WO2003074571A2 (en) * 2002-02-28 2003-09-12 Keck Graduate Institute Cationic polyelectrolytes in biomolecule purification and analysis
US9870907B2 (en) * 2002-03-11 2018-01-16 Jp Scientific Limited Probe for extraction of molecules of interest from a sample
US20090026122A1 (en) 2002-03-11 2009-01-29 Janusz Biocompatible solid-phase microextraction coatings and methods for their preparation
US9733234B2 (en) 2002-03-11 2017-08-15 Jp Scientific Limited Probe for extraction of molecules of interest from a sample
US20060084059A1 (en) * 2002-04-08 2006-04-20 Tai-Tung Yip Serum biomarkers in hepatocellular carcinoma
AUPS177202A0 (en) * 2002-04-16 2002-05-23 Diakyne Pty Ltd Multi-element screening of trace elements
AU2003265769A1 (en) * 2002-05-02 2003-11-17 Ciphergen Biosystems, Inc. Biochips with surfaces coated with polysaccharide based hydrogels
WO2004030511A2 (en) * 2002-05-10 2004-04-15 Eastern Virginia Medical School Prostate cancer biomarkers
US20040033613A1 (en) * 2002-05-30 2004-02-19 Zwick Michael G. Saliva-based protein profiling
WO2003101394A2 (en) * 2002-05-31 2003-12-11 Ciphergen Biosystems, Inc. Defensins: use as antiviral agents
US7109038B2 (en) * 2002-06-13 2006-09-19 The Johns Hopkins University Occult blood detection in biological samples by laser desorption and matrix-assisted laser desorption/ionization mass spectrometry for biomedical applications
WO2004009798A2 (en) * 2002-07-24 2004-01-29 Ciphergen Biosystems, Inc. Protein interaction difference mapping
AR040712A1 (en) 2002-07-29 2005-04-20 Correlogic Systems Inc A METHOD FOR INITIATING A CONTROL MODEL FOR THE BIO TEST PROCESS
US6624409B1 (en) 2002-07-30 2003-09-23 Agilent Technologies, Inc. Matrix assisted laser desorption substrates for biological and reactive samples
WO2004013290A2 (en) * 2002-08-05 2004-02-12 Invitrogen Corporation Compositions and methods for molecular biology
JP4644123B2 (en) * 2002-08-06 2011-03-02 ザ・ジョンズ・ホプキンス・ユニバーシティ Use of biomarkers to detect ovarian cancer
AU2003304434A1 (en) * 2002-08-06 2005-03-07 The Johns Hopkins University System, software and methods for biomarker identification
US20050233473A1 (en) * 2002-08-16 2005-10-20 Zyomyx, Inc. Methods and reagents for surface functionalization
WO2004016586A2 (en) * 2002-08-16 2004-02-26 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens
US20030119063A1 (en) * 2002-09-03 2003-06-26 Pham Thang T. High accuracy protein identification
US20040050787A1 (en) * 2002-09-13 2004-03-18 Elena Chernokalskaya Apparatus and method for sample preparation and direct spotting eluants onto a MALDI-TOF target
WO2004024318A1 (en) * 2002-09-13 2004-03-25 Pall Corporation Preparation and use of mixed mode solid substrates for chromatography adsorbents and biochip arrays
US20060292701A1 (en) * 2002-09-13 2006-12-28 Ciphergen Biosystems Inc. Photocrosslinked hydrogel blend surface coatings
US7045366B2 (en) * 2003-09-12 2006-05-16 Ciphergen Biosystems, Inc. Photocrosslinked hydrogel blend surface coatings
KR20050070034A (en) 2002-10-04 2005-07-05 미쯔비시 웰 파마 가부시키가이샤 Plate for mass spectrometry, process for preparing the same and use thereof
EP1572978A4 (en) * 2002-10-16 2006-05-24 Univ Texas Bead bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries
US7122384B2 (en) * 2002-11-06 2006-10-17 E. I. Du Pont De Nemours And Company Resonant light scattering microparticle methods
AU2003291483A1 (en) 2002-11-12 2004-06-03 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
MXPA05005071A (en) 2002-11-12 2005-07-22 Becton Dickinson Co Diagnosis of sepsis or sirs using biomarker profiles.
JP2006511790A (en) * 2002-11-14 2006-04-06 サイファージェン バイオシステムズ インコーポレイテッド Biomarkers for intra-amniotic inflammation
US7105809B2 (en) * 2002-11-18 2006-09-12 3M Innovative Properties Company Microstructured polymeric substrate
US7846748B2 (en) * 2002-12-02 2010-12-07 The University Of North Carolina At Chapel Hill Methods of quantitation and identification of peptides and proteins
EP1739185A1 (en) 2002-12-18 2007-01-03 Ciphergen Biosystems, Inc. Serum biomarkers in lung cancer
JP2006512076A (en) * 2002-12-31 2006-04-13 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Canine L-PBE sequence
WO2004057940A2 (en) * 2002-12-31 2004-07-15 Pharmacia & Upjohn Company Llc Canine dioxin/aryl hydrocarbon receptor sequences
JP2006512075A (en) * 2002-12-31 2006-04-13 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Canine CYP1A2 sequence
US20170212128A1 (en) 2004-01-13 2017-07-27 Tianxin Wang Methods and compositions for mass spectrometry analysis
US8119416B2 (en) * 2004-01-13 2012-02-21 Wuxi WeiYi Zhinengkeji, Inc. MALDI analysis using modified matrices with affinity groups for non-covalent binding with analytes
DE112004000250T5 (en) * 2003-02-10 2006-02-16 Waters Investments Ltd., New Castle Sample preparation plate for mass spectrometry
WO2005029003A2 (en) * 2003-02-10 2005-03-31 Waters Investments Limited Identification of air components with silicon mass spectrometry
US20060141470A1 (en) * 2003-02-14 2006-06-29 Kalayoglu Murat V Chlamydia pneumoniae associated chronic intraocular disorders and treatment thereof
DE10311384A1 (en) * 2003-03-11 2004-09-30 Universität Potsdam Detection method for plant molecules
US20040185448A1 (en) * 2003-03-20 2004-09-23 Viorica Lopez-Avila Methods and devices for performing matrix assisted laser desorption/lonization protocols
US6977370B1 (en) * 2003-04-07 2005-12-20 Ciphergen Biosystems, Inc. Off-resonance mid-IR laser desorption ionization
US20050233390A1 (en) * 2003-04-09 2005-10-20 Allen John W Device including a proteinaceous factor, a recombinant proteinaceous factor, and a nucleotide sequence encoding the proteinaceous factor
WO2004094460A2 (en) 2003-04-17 2004-11-04 Ciphergen Biosystems, Inc. Polypeptides related to natriuretic peptides and methods of their identification and use
EP1616180A4 (en) * 2003-04-22 2006-07-19 Ciphergen Biosystems Inc Methods of host cell protein analysis
US20060177870A1 (en) * 2003-04-28 2006-08-10 Ciphergen Biosystems, Inc Immunoassays
US7138625B2 (en) * 2003-05-02 2006-11-21 Agilent Technologies, Inc. User customizable plate handling for MALDI mass spectrometry
WO2004103155A2 (en) * 2003-05-16 2004-12-02 Ciphergen Biosystems, Inc. Surface-enhanced laser desorption/ionization-based disease diagnosis
CA2526691A1 (en) * 2003-05-23 2005-04-28 Board Of Regents - The University Of Texas System High throughput screening of aptamer libraries for specific binding to proteins on viruses and other pathogens
US7910523B2 (en) * 2003-05-23 2011-03-22 Board Of Regents, The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors
WO2004111654A2 (en) * 2003-06-06 2004-12-23 Ciphergen Biosystems, Inc. Serum biomarkers in ischaemic heart disease
US20050023456A1 (en) * 2003-06-09 2005-02-03 The Regents Of The University Of California Matrix for MALDI analysis based on porous polymer monoliths
WO2005008247A2 (en) * 2003-07-11 2005-01-27 Science & Technology Corporation @ Unm. Detection of endometrial pathology
US20050032113A1 (en) * 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
US20050118611A1 (en) * 2003-07-24 2005-06-02 Board Of Regents, The University Of Texas System Thioaptamers enable discovery of physiological pathways and new therapeutic strategies
SG145705A1 (en) * 2003-08-01 2008-09-29 Correlogic Systems Inc Multiple high-resolution serum proteomic features for ovarian cancer detection
US6977143B1 (en) * 2003-09-08 2005-12-20 Quest Diagnostics Investments Incorporated Determination of testosterone by mass spectrometry
US20050079631A1 (en) * 2003-10-09 2005-04-14 Science & Engineering Services, Inc. Method and apparatus for ionization of a sample at atmospheric pressure using a laser
US20050112650A1 (en) * 2003-10-20 2005-05-26 Ciphergen Biosystems, Inc. Reactive polyurethane-based polymers
AU2004286240A1 (en) * 2003-10-23 2005-05-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Biomarkers for amyotrophic lateral sclerosis
EP2369348A1 (en) 2003-11-07 2011-09-28 Ciphergen Biosystems, Inc. Biomarkers for Alzheimer's disease
US8043825B2 (en) * 2003-12-05 2011-10-25 Mcgill University Serum biomarkers for Chagas disease
US20050186645A1 (en) * 2003-12-18 2005-08-25 Yehudit Amor Method for analyzing a glycomolecule
WO2005061532A1 (en) * 2003-12-23 2005-07-07 Berthet Francois Xavier Pathogenic infection detection compositions and methods
US7183544B2 (en) * 2003-12-31 2007-02-27 Ciphergen Biosystems Inc. Bi-functional polymer chip
US20050181398A1 (en) * 2004-01-16 2005-08-18 Fung Eric T. Specific detection of host response protein clusters
US8021889B2 (en) * 2004-01-20 2011-09-20 Pall Corporation Chromatographic material for the absorption of proteins at physiological ionic strength
US20050181513A1 (en) * 2004-02-18 2005-08-18 Viorica Lopez-Avila Methods and compositions for assessing a sample by MAILDI mass spectrometry
US20050233400A1 (en) * 2004-03-03 2005-10-20 Weiner Carl P Proteomic method for predicting success of rescue cerclage
EP1580559B1 (en) 2004-03-23 2013-12-25 Bio-Rad Laboratories, Inc. Methods for reducing the variance between analyte concentrations taken from complex sample mixtures
US20060275923A1 (en) * 2004-03-23 2006-12-07 Hammond David J Methods for reducing the range in concentrations of analyte species in a sample
CA2578670C (en) 2004-04-15 2017-03-07 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
US20050239134A1 (en) * 2004-04-21 2005-10-27 Board Of Regents, The University Of Texas System Combinatorial selection of phosphorothioate single-stranded DNA aptamers for TGF-beta-1 protein
EP2520310B1 (en) * 2004-04-23 2016-03-30 Zoetis Services LLC Cellular permissivity factor for viruses, and uses thereof
WO2005103281A2 (en) 2004-04-26 2005-11-03 Children's Medical Center Corporation Platelet biomarkers for the detection of disease
US20060023808A1 (en) * 2004-05-17 2006-02-02 Hajivandi Mahbod R Compositions, kits, and methods for calibration in mass spectrometry
US20090215192A1 (en) * 2004-05-27 2009-08-27 Stratos Biosystems, Llc Solid-phase affinity-based method for preparing and manipulating an analyte-containing solution
ATE534750T1 (en) 2004-07-30 2011-12-15 Adeza Biomedical Corp ONCOFETAL FIBRONECTIN AS A CERVICAL CARCINOMA MARKER
US7786261B2 (en) * 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
CA2480549A1 (en) 2004-09-15 2006-03-15 Phytronix Technologies Inc. Ionization source for mass spectrometer
US7391018B2 (en) * 2004-09-17 2008-06-24 Nanosys, Inc. Nanostructured thin films and their uses
WO2006034278A2 (en) * 2004-09-21 2006-03-30 Matritech, Inc. Methods and compositions for detecting cancer using components of the u2 spliceosomal particle
EP1802961A4 (en) * 2004-09-29 2007-11-14 Bio Rad Laboratories Host-guest enery-absorbing complex
WO2006047417A2 (en) 2004-10-21 2006-05-04 University Of Florida Research Foundation, Inc. Detection of cannabinoid receptor biomarkers and uses thereof
JP4636859B2 (en) 2004-11-25 2011-02-23 キヤノン株式会社 Information acquisition method
US20060121619A1 (en) * 2004-12-02 2006-06-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Protein biomarkers and therapeutic targets in an animal model for amyotrophic lateral sclerosis
US7572596B2 (en) * 2004-12-02 2009-08-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Modulation of the neuroendoctrine system as a therapy for motor neuron disease
US20080003599A1 (en) * 2004-12-28 2008-01-03 Dary Ekaterina L Biological Microchip for Multiple Parallel Immunoassay of Compounds and Immunoassay Metods Using Said Microchip
EP1838867B1 (en) * 2005-01-06 2011-03-09 Eastern Virginia Medical School Apolipoprotein a-ii isoform as a biomarker for prostate cancer
CN101268368A (en) 2005-01-28 2008-09-17 儿童医疗中心有限公司 Methods for diagnosis and prognosis of epithelial cancers
JP2008530555A (en) * 2005-02-09 2008-08-07 コレロジック システムズ,インコーポレイテッド Identification of bacteria and spores
US20060183863A1 (en) * 2005-02-14 2006-08-17 Ciphergen Biosystems, Inc. Zwitterionic polymers
US20090247421A1 (en) * 2005-03-23 2009-10-01 Egisto Boschetti Diverse chemical libraries bound to small particles with paramagnetic properties
JP2008538112A (en) * 2005-03-23 2008-10-09 バイオ−ラッド ラボラトリーズ インコーポレーティッド Diverse chemical libraries bound to small particles with paramagnetic properties
US8048638B2 (en) * 2005-04-01 2011-11-01 University Of Florida Research Foundation, Inc. Biomarkers of liver injury
US7645584B2 (en) * 2005-04-01 2010-01-12 University Of Florida Research Foundation, Inc. Biomarkers of liver injury
US7972867B2 (en) * 2005-04-06 2011-07-05 Quest Diagnostics Investments Incorporated Methods for detecting vitamin D metabolites by mass spectrometry
US7745226B2 (en) 2005-04-06 2010-06-29 Quest Diagnostics Investments Incorporated Methods for detecting vitamin D metabolites
BRPI0609302A2 (en) 2005-04-15 2011-10-11 Becton Dickinson Co methods for predicting the development of sepsis and for diagnosing sepsis in an individual to be tested, microarray, kit for predicting the development of sepsis in an individual to be tested, computer program product, computer, computer system for determining if an individual is likely to develop sepsis, digital signal embedded in a carrier wave, and, graphical user interface to determine if an individual is likely to develop sepsis
US7622273B2 (en) * 2005-05-11 2009-11-24 Gibbs Bernard F Method for chemical and enzymatic treatment of posttranslationally modified proteins bound to a protein chip
WO2006124628A2 (en) * 2005-05-12 2006-11-23 Correlogic Systems, Inc. A model for classifying a biological sample in relation to breast cancer based on mass spectral data
WO2006124644A2 (en) * 2005-05-12 2006-11-23 Board Of Regents, The University Of Texas System Protein and antibody profiling using small molecule microarrays
WO2006125094A2 (en) * 2005-05-18 2006-11-23 Board Of Regents, The University Of Texas System Combinatorial selection of phosphorothioate aptamers for rnases
US20060261267A1 (en) * 2005-05-20 2006-11-23 Agency For Science, Technology And Research Composite MALDI matrix material and methods of using it and kits thereof in MALDI
US7435951B2 (en) * 2005-06-08 2008-10-14 Agilent Technologies, Inc. Ion source sample plate illumination system
EP1896493A1 (en) 2005-06-17 2008-03-12 North Carolina A & T State University A device including a proteinaceous factor, a recombinant proteinaceous factor, and a nucleotide sequence encoding the proteinaceous factor
EP2993474B1 (en) 2005-06-24 2019-06-12 Vermillion, Inc. Biomarkers for ovarian cancer: beta-2 microglobulin
ITTO20050569A1 (en) * 2005-08-09 2007-02-10 St Microelectronics Srl DEVICE AND METHOD OF DETERMINING THE CONTACT POSITION AND CONTACT SENSITIVE ELECTRONIC DEVICE
US7495231B2 (en) * 2005-09-08 2009-02-24 Agilent Technologies, Inc. MALDI sample plate imaging workstation
DE102005044307B4 (en) * 2005-09-16 2008-04-17 Bruker Daltonik Gmbh Ionization of desorbed molecules
US20070202515A1 (en) * 2005-10-12 2007-08-30 Pathologica, Llc. Promac signature application
CA2627966A1 (en) 2005-11-16 2007-05-24 Novartis Ag Biomarkers for anti-nogo-a antibody treatment in spinal cord injury
WO2007061981A2 (en) * 2005-11-21 2007-05-31 Lumera Corporation Surface plasmon resonance spectrometer with an actuator-driven angle scanning mechanism
US20070127164A1 (en) * 2005-11-21 2007-06-07 Physical Logic Ag Nanoscale Sensor
US7463358B2 (en) * 2005-12-06 2008-12-09 Lumera Corporation Highly stable surface plasmon resonance plates, microarrays, and methods
WO2007070809A2 (en) * 2005-12-12 2007-06-21 Mcgill University Biomarkers for babesia
US9347945B2 (en) 2005-12-22 2016-05-24 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
ES2606015T3 (en) 2005-12-22 2017-03-17 Abbott Molecular Inc. Methods and combinations of markers for the detection of lung cancer predisposition
US20090215085A1 (en) * 2006-01-27 2009-08-27 Eastern Virginia Medical School Proteomic Fingerprinting of Human IVF-Derived Embryos: Identification of Biomarkers of Developmental Potential
JP2009527735A (en) 2006-02-17 2009-07-30 チルドレンズ メディカル センター コーポレーション Free NGAL as a biomarker for cancer
EP1994314A4 (en) * 2006-03-06 2011-10-26 Acs Ind Inc Sliding sealing connector
WO2007120999A2 (en) * 2006-03-06 2007-10-25 Bio-Rad Laboratories, Inc. Chelating monomers and polymers
EP2469279A1 (en) 2006-03-11 2012-06-27 The Board Of Trustees Of The Leland Stanford Junior University Cystatin C, lysozyme and beta-2-microglobulin as biomarker for peripheral artery disease
US20070231916A1 (en) * 2006-03-29 2007-10-04 Cangen Biotechnologies, Inc. Apparatus and method for filtration to enhance the detection of peaks
US20070231915A1 (en) * 2006-03-29 2007-10-04 Cangen Biotechnologies, Inc. Apparatus and method for filtration to enhance the detection of peaks
KR20090027608A (en) * 2006-03-29 2009-03-17 칸젠 바이오테크날러지즈, 인코포레이티드 Methods of predicting response to a treatment for a disease
EP2010895A2 (en) * 2006-03-29 2009-01-07 Cangen Biotechnologies, Inc. Apparatus and method for predicting disease
US20070238193A1 (en) * 2006-03-29 2007-10-11 Cangen Biotechnologies, Inc. Apparatus and method for filtration to enhance the detection of peaks
US20070231917A1 (en) * 2006-03-29 2007-10-04 Cangen Biotechnologies, Inc. Apparatus and method for filtration to enhance the detection of peaks
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
WO2007123908A2 (en) * 2006-04-18 2007-11-01 Advanced Liquid Logic, Inc. Droplet-based multiwell operations
WO2007133714A2 (en) * 2006-05-12 2007-11-22 Stratos Biosystems, Llc Analyte focusing biochips for affinity mass spectrometry
CA2652251A1 (en) 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions of r(+) and s(-) pramipexole and methods for using the same
WO2007139956A2 (en) * 2006-05-26 2007-12-06 Laboratory Corporation Of America Holdings Methods and systems for the quantitative analysis of biomarkers
US20080193772A1 (en) * 2006-07-07 2008-08-14 Bio-Rad Laboratories, Inc Mass spectrometry probes having hydrophobic coatiings
US7972794B2 (en) * 2006-07-18 2011-07-05 Quest Diagnostics Investments Incorporated Oxidized apoA-I determination by mass spectrometry
WO2008011158A2 (en) 2006-07-21 2008-01-24 Amgen Inc. Method of detecting and/ or measuring hepcidin in a sample
AT504100B9 (en) * 2006-08-25 2009-12-15 Leopold Franzens Uni Innsbruck MATRIX-FREE MALDI MASS SPECTROMETRY
ES2655564T3 (en) 2006-09-07 2018-02-20 Otago Innovation Limited Biomarker for the early detection of acute heart disorders
US8017015B2 (en) * 2006-10-20 2011-09-13 Quest Diagnostics Investments Incorporated Monolithic column chromatography
US20080128608A1 (en) * 2006-11-06 2008-06-05 The Scripps Research Institute Nanostructure-initiator mass spectrometry
JP2010511147A (en) * 2006-11-23 2010-04-08 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Device for separation of analytes in samples and MALDI analysis
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
EP2114396A4 (en) * 2006-12-29 2010-03-10 Salk Inst For Biological Studi Methods for enhancing exercise performance
JP4984900B2 (en) * 2007-01-12 2012-07-25 株式会社島津製作所 Mass spectrometry using polymer-coated microparticles
US20080201095A1 (en) * 2007-02-12 2008-08-21 Yip Ping F Method for Calibrating an Analytical Instrument
EP2136843A1 (en) 2007-03-12 2009-12-30 Miraculins Inc. Biomarkers of prostate cancer and uses thereof
JP2010521496A (en) 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク. Synthesis of chiral purified substituted benzothiazolediamine
AU2008236810A1 (en) 2007-03-27 2008-10-16 Board Of Regents Of The University Of Texas System Biomarkers for ovarian cancer
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
EP2639316A1 (en) 2007-05-11 2013-09-18 The Johns Hopkins University Biomarkers for melanoma
US9091695B2 (en) * 2007-06-01 2015-07-28 Laboratory Corporation Of America Holdings Methods and systems for quantification of peptides and other analytes
US20100184110A1 (en) * 2007-06-06 2010-07-22 Siemens Healthcare Diagnostics Inc. Predictive diagnostics for kidney disease
US8017403B2 (en) 2007-06-14 2011-09-13 Quest Diagnostics Investments Incorporated Mass spectrometry method for measuring vitamin B6 in body fluid
ES2609818T3 (en) 2007-06-15 2017-04-24 Xiamen University Monoclonal antibodies that bind to H5 subtype avian influenza virus hemagglutinin and uses thereof
CA3056116A1 (en) 2007-06-22 2008-12-31 Randolph Watnick Methods and uses thereof of prosaposin
JP2010532484A (en) 2007-06-29 2010-10-07 コレロジック システムズ,インコーポレイテッド Predictive markers for ovarian cancer
US11311917B2 (en) 2007-08-09 2022-04-26 Bruker Nano, Inc. Apparatus and method for contamination identification
US20090060786A1 (en) * 2007-08-29 2009-03-05 Gibum Kim Microfluidic apparatus for wide area microarrays
US20090180931A1 (en) 2007-09-17 2009-07-16 Sequenom, Inc. Integrated robotic sample transfer device
WO2009058331A2 (en) 2007-10-29 2009-05-07 Vermilllion, Inc. Biomarkers for the detection of early stage ovarian cancer
WO2009061313A1 (en) * 2007-11-06 2009-05-14 The Scripps Research Institute Nanostructure-initiator mass spectrometry
US20090134325A1 (en) 2007-11-27 2009-05-28 Goldman Mildred M Methods for detecting estradiol by mass spectrometry
US7972868B2 (en) 2007-11-28 2011-07-05 Quest Diagnostics Investments Incorporated Methods for detecting dihydroxyvitamin D metabolites by mass spectrometry
WO2009070350A1 (en) 2007-11-30 2009-06-04 Siemens Healthcare Diagnostics Inc. Adiponectin receptor fragments and methods of use
US8030084B2 (en) 2007-12-06 2011-10-04 Quest Diagnostics Investments Incorporated Thyroglobulin quantitation by mass spectrometry
US8916385B2 (en) 2007-12-13 2014-12-23 Quest Diagnostics Investments, Inc. Methods for detecting estrone by mass spectrometry
US8004669B1 (en) 2007-12-18 2011-08-23 Plexera Llc SPR apparatus with a high performance fluid delivery system
TW200933195A (en) * 2008-01-28 2009-08-01 Ind Tech Res Inst Autostereoscopic display
EP2265641B1 (en) * 2008-03-12 2018-01-24 Otago Innovation Limited Biomarkers
EP2265642A4 (en) 2008-03-12 2012-05-02 Otago Innovation Ltd Biomarkers
US20110008903A1 (en) * 2008-03-27 2011-01-13 Valerie Paradis Methods and kits for determining the occurrence of a liver disease in a subject
US8669113B2 (en) 2008-04-03 2014-03-11 Becton, Dickinson And Company Advanced detection of sepsis
JP5258360B2 (en) * 2008-04-14 2013-08-07 富士フイルム株式会社 Immunochromatography measurement method and immunochromatography measurement kit
US7776522B2 (en) 2008-04-24 2010-08-17 Becton, Dickinson And Company Methods for diagnosing oncogenic human papillomavirus (HPV)
US8673644B2 (en) 2008-05-13 2014-03-18 Battelle Memorial Institute Serum markers for type II diabetes mellitus
EP2286437A1 (en) * 2008-06-02 2011-02-23 Bio-Rad Laboratories, Inc. Mass spectrometric detection of material transferred to a surface
WO2010123720A1 (en) 2009-04-23 2010-10-28 Siemens Healthcare Diagnostics Inc. Monomeric and dimeric forms of adiponectin receptor fragments and methods of use
US7834313B2 (en) * 2008-08-08 2010-11-16 Quest Diagnostics Investments Incorporated Mass spectrometry assay for plasma-renin
US8106351B2 (en) 2008-08-08 2012-01-31 Quest Diagnostics Investments Incorporated Mass spectrometry assay for plasma-renin
JP5781436B2 (en) 2008-08-11 2015-09-24 バンヤン・バイオマーカーズ・インコーポレーテッド Biomarker detection methods and assays for neurological conditions
EP2334185A4 (en) 2008-08-19 2011-09-21 Knopp Neurosciences Inc Compositions and methods of using (r)-pramipexole
US7893399B2 (en) * 2008-09-09 2011-02-22 Quest Diagnostics Investments Incorporated Methods for detecting dehydroepiandrosterone by mass spectrometry
US7804063B2 (en) 2008-10-06 2010-09-28 Quest Diagnostics Investments Incorporated Methods for detecting dihydrotestosterone by mass spectrometry
US7952067B2 (en) 2008-10-06 2011-05-31 Quest Diagnostics Investments Incorporated Methods for detecting vitamin C by mass spectrometry
EP2687609B1 (en) 2008-11-10 2017-01-04 The United States of America, as represented by The Secretary, Department of Health and Human Services Method for treating solid tumor
US8039794B2 (en) * 2008-12-16 2011-10-18 Quest Diagnostics Investments Incorporated Mass spectrometry assay for thiopurine-S-methyl transferase activity and products generated thereby
US7952068B2 (en) 2008-12-16 2011-05-31 Quest Diagnostics Investments Incorporated Methods for detecting catecholamines by mass spectrometry
US8399829B2 (en) 2008-12-18 2013-03-19 Quest Diagnostics Investments Incorporated Vitamin B2 detection by mass spectrometry
US20100155594A1 (en) 2008-12-23 2010-06-24 Goldman Mildred M Mass spectrometry assay for estrogenic compounds
WO2010075449A1 (en) * 2008-12-24 2010-07-01 Quest Diagnostics Investments Incorporated Mass spectrometry assay for congenital adrenal hyperplasia
US8535891B2 (en) 2008-12-30 2013-09-17 Children's Medical Center Corporation Method of predicting acute appendicitis
WO2010079253A2 (en) 2009-01-09 2010-07-15 Proyecto De Biomedicina Cima, S.L. Bio-markers for diagnosing fibrosis
WO2010087985A2 (en) 2009-01-28 2010-08-05 Yale University Novel markers for detection of complications resulting from in utero encounters
US8715928B2 (en) 2009-02-13 2014-05-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molecular-based method of cancer diagnosis and prognosis
MX2011012680A (en) * 2009-05-29 2012-03-06 Univ Texas Peptoid ligands for isolation and treatment of autoimmune t-cells.
CN102439451B (en) * 2009-06-02 2014-12-03 德克萨斯大学系统董事会 Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
JP4993632B2 (en) * 2009-06-16 2012-08-08 朝日インテック株式会社 Medical guidewire
WO2011012672A1 (en) 2009-07-29 2011-02-03 Pharnext New diagnostic tools for alzheimer disease
WO2011047257A1 (en) * 2009-10-16 2011-04-21 The Board Of Regents Of The University Of Texas System Compositions and methods for producing cyclic peptoid libraries
WO2011057021A1 (en) 2009-11-05 2011-05-12 Quest Diagnostics Investments Incorporated Quantitation of insulin-like growth factor-i and insulin-like growth factor-ii with high-resolution mass spectrometry
US8304248B2 (en) 2009-11-16 2012-11-06 Torres Anthony R Protein separation via ion-exchange chromatography and associated methods, systems, and devices
US8034627B2 (en) 2009-12-03 2011-10-11 Quest Diagnostics Investments Incorporated Methods for detecting dihydroxyvitamin D metabolites by mass spectrometry
US7977117B2 (en) * 2009-12-03 2011-07-12 Quest Diagnostics Investments Incorprated Vitamin D metabolite determination utilizing mass spectrometry following derivatization
JP5739903B2 (en) 2009-12-11 2015-06-24 クエスト ダイアグノスティックス インヴェストメンツ インコーポレイテッド Mass spectrometry of steroidal compounds in complex samples
JP6113504B2 (en) 2009-12-11 2017-04-12 クエスト ダイアグノスティックス インヴェストメンツ インコーポレイテッド Determination of non-derivatized non-metabolized vitamin D by mass spectrometry
EP3366695B1 (en) 2009-12-17 2021-07-07 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
WO2011084751A1 (en) * 2009-12-21 2011-07-14 Quest Diagnostics Investments Incorporated Glucagon detection and quantitation by mass spectrometry
ES2735530T3 (en) 2010-01-26 2019-12-19 Bioregency Inc Compositions and methods related to argininosuccinate synthetase
WO2011149943A1 (en) 2010-05-24 2011-12-01 Ventana Midical Systems, Inc. Method for differentiation of non-small cellung carcinoma
US10837972B2 (en) 2010-06-09 2020-11-17 Quest Diagnostics Investments Incorporated Mass spectrometric determination of derivatized methylmalonic acid
AU2011282245B2 (en) 2010-07-19 2017-09-28 Otago Innovation Limited Signal biomarkers
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
WO2012051519A2 (en) 2010-10-14 2012-04-19 The Johns Hopkins University Biomarkers of brain injury
WO2012087438A1 (en) 2010-11-08 2012-06-28 Georgetown University Methods for simultaneous quantification of thyroid hormones and metabolites thereof by mass spectrometry
US10436803B2 (en) 2010-12-28 2019-10-08 Quest Diagnostics Investments Incorporated Quantitation of insulin by tandem mass spectrometry of insulin B chain
US9177766B2 (en) 2010-12-30 2015-11-03 Quest Diagnostics Investments Incorporated Mass spectrometric quantitation assay for metabolites of leflunomide
JP2014518624A (en) 2011-05-12 2014-08-07 ザ・ジョンズ・ホプキンス・ユニバーシティー Assay reagent for neurogranin diagnostic kit
US8728824B2 (en) 2011-06-22 2014-05-20 Quest Diagnostics Investments Inc. Mass spectrometric determination of fatty acids
CA2839451A1 (en) 2011-06-27 2013-01-03 The Jackson Laboratory Methods and compositions for treatment of cancer and autoimmune disease
WO2013055911A1 (en) 2011-10-14 2013-04-18 Dana-Farber Cancer Institute, Inc. Znf365/zfp365 biomarker predictive of anti-cancer response
AU2012340015B2 (en) 2011-11-14 2017-09-21 Alfasigma S.P.A. Assays for selecting a treatment regimen for a subject with depression and methods for treatment
EP2783388A4 (en) 2011-11-23 2015-12-09 Quest Diagnostics Invest Inc Kisspeptin-54 detection by tandem mass spectrometry
US8669519B2 (en) 2011-12-05 2014-03-11 Quest Diagnostics Investments, Inc. Methods for detecting reverse triiodothyronine by mass spectrometry
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
EP3560509B1 (en) 2011-12-22 2024-01-31 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
US8779355B2 (en) 2011-12-28 2014-07-15 Quest Diagnostics Investments, Inc. Methods for detecting lacosamide by mass spectrometry
RU2674153C2 (en) 2012-01-05 2018-12-05 Бостон Медикал Сентер Корпорэйшн Slit-robo signalling for diagnosis and treatment of kidney disease
AU2013210776B2 (en) 2012-01-20 2018-11-22 Adelaide Research & Innovation Pty Ltd Biomarkers for gastric cancer and uses thereof
WO2013112216A1 (en) 2012-01-24 2013-08-01 Cd Diagnostics, Llc System for detecting infection in synovial fluid
US9360454B2 (en) 2012-03-02 2016-06-07 Berg Llc Methods and kits for detection of coenzyme Q10
IN2014DN08537A (en) 2012-03-20 2015-05-15 Otago Innovation Ltd
WO2013192616A1 (en) 2012-06-22 2013-12-27 Htg Molecular Diagnostics, Inc. Molecular malignancy in melanocytic lesions
EP2680005A1 (en) 2012-06-28 2014-01-01 Rheinische Friedrich-Wilhelms-Universität Bonn Lipid analysis
US9638687B2 (en) 2012-08-28 2017-05-02 Bloodworks Biochemical markers of red blood cell storage and toxicity
EP3392344B1 (en) 2012-09-20 2021-10-27 Quest Diagnostics Investments Incorporated Thyroglobulin quantitation by mass spectroscopy
AU2013202668B2 (en) 2012-12-24 2014-12-18 Adelaide Research & Innovation Pty Ltd Inhibition of cancer growth and metastasis
JP6301362B2 (en) 2012-12-26 2018-03-28 クエスト ダイアグノスティックス インヴェストメンツ インコーポレイテッド C-peptide detection by mass spectrometry
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
WO2014182896A1 (en) 2013-05-10 2014-11-13 Johns Hopkins University Compositions for ovarian cancer assessment having improved specificity
CA2913334A1 (en) 2013-05-23 2014-11-27 Iphenotype Llc Method and system for maintaining or improving wellness
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
LT3019167T (en) 2013-07-12 2021-03-25 Knopp Biosciences Llc Treating elevated levels of eosinophils and/or basophils
EP3757226A3 (en) 2013-07-17 2021-05-05 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
WO2015020523A1 (en) 2013-08-07 2015-02-12 Stichting Vu-Vumc Biomarkers for early diagnosis of alzheimer's disease
HUE055850T2 (en) 2013-08-13 2022-01-28 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
EP3038467B1 (en) 2013-08-13 2020-07-29 Knopp Biosciences LLC Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
WO2015030585A2 (en) 2013-08-27 2015-03-05 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Methods for detecting post-translationally modified lysines in a polypeptide
CN103822964B (en) * 2013-10-21 2016-02-24 南昌大学 Chloromycetin in neutral desorb-electron spray extraction MALDI-MS direct-detection honey
WO2015073709A2 (en) 2013-11-14 2015-05-21 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Detection of atherosclerotic cardiovascular disease risk and heart failure risk
PL3083997T3 (en) 2013-12-20 2021-04-06 Université de Lausanne Diagnostic, prognostic and therapeutic uses of long noncoding rnas for heart disease and regenerative medicine
WO2015106003A1 (en) 2014-01-08 2015-07-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Ras pathways as markers of protection against hiv and methods to improve vaccine efficacy
WO2015152724A2 (en) 2014-04-02 2015-10-08 Stichting Vu-Vumc Biomarkers for the detection of frontotemporal dementia
WO2015164743A2 (en) 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
EP4220178A3 (en) 2014-05-12 2023-08-16 Quest Diagnostics Investments Incorporated Quantitation of tamoxifen and metabolites thereof by mass spectrometry
WO2015188282A1 (en) * 2014-06-13 2015-12-17 Pawliszyn Janusz B A probe for extraction of molecules of interest from a sample
WO2015200697A1 (en) 2014-06-25 2015-12-30 The General Hospital Corporation Targeting human satellite ii (hsatii)
US10222386B2 (en) 2014-09-19 2019-03-05 The Johns Hopkins University Biomarkers of congnitive dysfunction
US9963667B2 (en) 2014-12-31 2018-05-08 Fluidigm Canada Inc. Structured biological samples for analysis by mass cytometry
US20180003721A1 (en) 2015-01-15 2018-01-04 Joslin Diabetes Center Metabolite Biomarkers Predictive Of Renal Disease In Diabetic Patients
JP6813503B2 (en) 2015-02-10 2021-01-13 ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング Free histone protein as a biomarker
US11041865B2 (en) 2015-02-20 2021-06-22 The Johns Hopkins University Biomarkers of myocardial injury
US10324082B2 (en) 2015-03-03 2019-06-18 Quest Diagnostics Investments Llc Methods for quantitation of insulin levels by mass spectrometry
EP3294332A4 (en) 2015-05-14 2018-12-26 Joslin Diabetes Center, Inc. Retinol-binding protein 3 (rbp3) as a protective factor in non-diabetic retinal degeneration
WO2017023929A1 (en) 2015-08-04 2017-02-09 Cd Diagnostics, Inc. Methods for detecting adverse local tissue reaction (altr) necrosis
US11360098B2 (en) 2015-09-28 2022-06-14 Quest Diagnostics Investments Llc Amyloid beta detection by mass spectrometry
WO2017099829A1 (en) 2015-12-11 2017-06-15 The General Hospital Corporation Compositions and methods for treating drug-tolerant glioblastoma
JP7085485B2 (en) 2016-01-15 2022-06-16 マサチューセッツ アイ アンド イヤー インファーマリー Secretory P-glycoprotein is a non-invasive biomarker for chronic nasal sinusitis
WO2017125406A1 (en) 2016-01-19 2017-07-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting left ventricular remodeling in subjects suffering from hypertension
CN108884495B (en) 2016-02-08 2023-08-22 美国政府(由卫生和人类服务部的部长所代表) Gene markers predict the response of hepatocellular carcinoma to Transcatheter Arterial Chemoembolization (TACE)
WO2017147186A1 (en) 2016-02-22 2017-08-31 Ursure, Inc. System and method for detecting therapeutic agents to monitor adherence to a treatment regimen
EP3423186A4 (en) 2016-03-02 2019-10-23 JP Scientific Limited Solid phase microextraction coating
CA3019256A1 (en) 2016-05-10 2017-11-16 Jp Scientific Limited System and method for desorbing and detecting an analyte sorbed on a solid phase microextraction device
KR101747038B1 (en) 2016-06-27 2017-06-15 이현영 Nanopolymer Having Heteromorphic Polymer Structure, Preparation Method Thereof, Nucleic Acid Reaction Composition Containing Thereof, and Method of Detecting or Quantifying Nucleic Acid Using Nucleic Acid Reaction Composition Containing Thereof
CN110366558A (en) 2016-10-28 2019-10-22 班扬生物标记公司 For the antibody and correlation technique of ubiquitin c-terminal hydrolase-l 1 (UCH-L1) and glial fibrillary acid protein (GFAP)
US11448648B2 (en) 2016-11-11 2022-09-20 Ascendant Diagnostics, LLC Compositions and methods for diagnosing and differentiating systemic juvenile idiopathic arthritis and Kawasaki disease
JP7337701B2 (en) 2017-03-31 2023-09-04 クエスト ダイアグノスティックス インヴェストメンツ エルエルシー Method for quantification of insulin and C-peptide
DE102017206155A1 (en) 2017-04-11 2018-10-11 Robert Bosch Gmbh Desorption of nucleic acids
MX2020001325A (en) 2017-07-31 2020-07-13 Quest Diagnostics Invest Llc Apolipoprotein e isotype detection by mass spectrometry.
US11860141B2 (en) 2017-08-14 2024-01-02 Quest Diagnostics Investments Llc Detection and quantitation of guanidinoacetate, creatine, and creatinine by mass spectrometry
KR102702206B1 (en) 2017-09-25 2024-09-02 프레드 허친슨 캔서 센터 High-efficiency targeted in situ genome-wide profiling
CN112533613A (en) 2018-02-06 2021-03-19 通用医疗公司 Repeated RNA as biomarker for tumor immune response
GB201802123D0 (en) 2018-02-09 2018-03-28 Metabolomic Diagnostics Ltd A method of processomg a biological sample
JP6916446B2 (en) * 2018-09-13 2021-08-11 日本電信電話株式会社 Base station management method, base station management device and program
WO2020053380A1 (en) 2018-09-14 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of amniotic fluid peptides for predicting postnatal renal function in congenital anomalies of the kidney and the urinary tract
US20220018852A1 (en) 2018-11-20 2022-01-20 Inserm (Institute National De Ka Santé Et De La Recherche Médicale) Methods and kits for detecting liver dysfunction in a subject
EP3677693A1 (en) 2019-01-03 2020-07-08 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Transpochimeric gene trancripts (tcgts) as cancer biomarkers
IL291806A (en) 2019-10-10 2022-06-01 Regeneron Pharma Liquid chromatography-mass spectrometry (lc-ms) methods for analyzing ampholyte lot variation
CN115552034A (en) 2020-01-31 2022-12-30 瑞泽恩制药公司 Use of liquid chromatography and mass spectrometry for the characterization of oligonucleotides
EP4133285A1 (en) 2020-04-09 2023-02-15 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and compositions to determine the quality of red blood cell units
IL296664A (en) 2020-04-24 2022-11-01 Hoffmann La Roche Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
CN115916405A (en) * 2020-05-20 2023-04-04 普度研究基金会 Integrated synthesis and analysis system and method of use
US12116637B2 (en) 2020-07-24 2024-10-15 The Regents Of The University Of Michigan Compositions and methods for detecting and treating high grade subtypes of uterine cancer
EP4229222A2 (en) 2020-10-19 2023-08-23 Dana-Farber Cancer Institute, Inc. Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
AU2021368138A1 (en) 2020-11-02 2023-06-22 Trethera Corporation Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof
CN112540118B (en) * 2020-12-03 2022-03-11 福州大学 Method for rapidly detecting metal ions based on mercaptobenzoic acid-assisted laser desorption ionization mass spectrum
CA3213700A1 (en) 2021-03-17 2022-09-22 Nissui Corporation Method of purification and purified products
EP4347889A1 (en) 2021-05-28 2024-04-10 Centre Hospitalier Universitaire Vaudois (CHUV) Novel incrna controlling cardiac fibrosis
WO2023122723A1 (en) 2021-12-23 2023-06-29 The Broad Institute, Inc. Panels and methods for diagnosing and treating lung cancer
US12105102B2 (en) 2022-03-30 2024-10-01 University Of Utah Research Foundation Methods for quantifying insulin-like growth factor-1 and insulin-like growth factor-2
WO2024074685A1 (en) 2022-10-07 2024-04-11 Institut National de la Santé et de la Recherche Médicale Use of albumin isoforms profiles for the characterization of the etiology and severity of liver injuries
WO2024196732A1 (en) 2023-03-17 2024-09-26 Quest Diagnostics Investments Llc Improved quantitation of testosterone in multiplexed samples by mass spectrometry

Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896661A (en) * 1974-01-09 1975-07-29 Stanford Research Inst Method of coupling thin layer chromatograph with mass spectrometer
US4022876A (en) * 1973-06-21 1977-05-10 Stanford Research Institute Mass spectrometric immunoassay
US4295046A (en) * 1975-09-11 1981-10-13 Leybold Heraeus Gmbh Mass spectrometer
US4296332A (en) * 1979-12-28 1981-10-20 Sperry Corporation Sprocket hole sensing detector for moving translucent paper sheets
US4298332A (en) * 1978-04-08 1981-11-03 Katashi Aoki Nozzle device for molding plastics
US4454233A (en) * 1981-10-21 1984-06-12 Wang Associates Method of tagged immunoassay
US4468468A (en) * 1981-06-27 1984-08-28 Bayer Aktiengesellschaft Process for the selective analysis of individual trace-like components in gases and liquid
US4686366A (en) * 1985-05-15 1987-08-11 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Laser mass spectrometer
US4694167A (en) * 1985-11-27 1987-09-15 Atom Sciences, Inc. Double pulsed time-of-flight mass spectrometer
US4705616A (en) * 1986-09-15 1987-11-10 Sepragen Corporation Electrophoresis-mass spectrometry probe
US4902627A (en) * 1985-02-05 1990-02-20 The United States Of America As Represented By The Secretary Of The Navy Method for detecting amine-containing drugs in body fluids by sims
US4988879A (en) * 1987-02-24 1991-01-29 The Board Of Trustees Of The Leland Stanford Junior College Apparatus and method for laser desorption of molecules for quantitation
US5003059A (en) * 1988-06-20 1991-03-26 Genomyx, Inc. Determining DNA sequences by mass spectrometry
US5045694A (en) * 1989-09-27 1991-09-03 The Rockefeller University Instrument and method for the laser desorption of ions in mass spectrometry
US5078135A (en) * 1989-05-31 1992-01-07 Board Of Regents, The University Of Texas System Apparatus for in vivo analysis of biological compounds in blood or tissue by microdialysis and mass spectrometry
US5118937A (en) * 1989-08-22 1992-06-02 Finnigan Mat Gmbh Process and device for the laser desorption of an analyte molecular ions, especially of biomolecules
US5124267A (en) * 1984-05-10 1992-06-23 Schering Aktiengesellschaft Method for the determination of small substance quantities of medicines, of endogenous or other chemical compounds in biological material
US5171989A (en) * 1992-01-24 1992-12-15 Board Of Trustees Of Leland Stanford Jr. University Method and apparatus for continuous sample ice matrix production for laser desorption in mass spectrometry
US5209919A (en) * 1990-07-13 1993-05-11 Regents Of The University Of California Method of measurement in biological systems
US5547835A (en) * 1993-01-07 1996-08-20 Sequenom, Inc. DNA sequencing by mass spectrometry
US5719060A (en) * 1993-05-28 1998-02-17 Baylor College Of Medicine Method and apparatus for desorption and ionization of analytes
US6020208A (en) * 1994-05-27 2000-02-01 Baylor College Of Medicine Systems for surface-enhanced affinity capture for desorption and detection of analytes
US6225047B1 (en) * 1997-06-20 2001-05-01 Ciphergen Biosystems, Inc. Use of retentate chromatography to generate difference maps
US6228047B1 (en) * 1997-07-28 2001-05-08 1274515 Ontario Inc. Method and apparatus for performing peritoneal dialysis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3201264A1 (en) * 1982-01-16 1983-07-28 Leybold-Heraeus GmbH, 5000 Köln LASER MICRO PROBE
DE3221681A1 (en) * 1982-06-08 1983-12-08 Bayer Ag, 5090 Leverkusen Mass spectrometer with an external sample holder
DE3321681A1 (en) 1983-06-15 1984-12-20 Fogra Deutsche Forschungsgesellschaft für Druck- und Reproduktionstechnik e.V., 8000 München Process for the removal of volatile substances from layers
US4665192A (en) * 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole
US6060237A (en) * 1985-02-26 2000-05-09 Biostar, Inc. Devices and methods for optical detection of nucleic acid hybridization
FR2586657B1 (en) * 1985-09-04 1991-03-22 Lapouyade Sa DEVICE FOR GRIPPING SUPPORTS OR LOAD CONTAINERS
JPS63124543A (en) * 1986-11-14 1988-05-28 Hitachi Electronics Eng Co Ltd Plate chucking mechanism
JPH01197211A (en) * 1988-01-30 1989-08-08 Canon Inc Device for driving pallet
DE3809504C1 (en) * 1988-03-22 1989-09-21 Bruker - Franzen Analytik Gmbh, 2800 Bremen, De
JPH0249209U (en) * 1988-09-29 1990-04-05
GB2235529B (en) * 1989-08-23 1993-07-28 Finnigan Mat Ltd Method of preparing samples for laser spectrometry analysis
GB2236185B (en) * 1989-08-22 1994-03-23 Finnigan Mat Gmbh Process,specimen and device for making an analyte available for an investigation
GB2235528B (en) * 1989-08-23 1993-07-28 Finnigan Mat Ltd Method of preparing samples for laser spectrometry analysis
GB2236184B (en) * 1989-09-12 1993-07-28 Finnigan Mat Ltd Method of preparing samples for laser spectrometry analysis
US5029919A (en) * 1990-02-15 1991-07-09 Bauer John K Pneumatic shock absorber for an automobile bumper having venting means
US5073713A (en) * 1990-05-29 1991-12-17 Battelle Memorial Institute Detection method for dissociation of multiple-charged ions
ES2067852T3 (en) * 1990-06-08 1995-04-01 Mannesmann Ag SHELVES INSTALLATION.
WO1992013629A1 (en) * 1991-01-31 1992-08-20 Wayne State University A method for analyzing an organic sample
US5317932A (en) * 1992-02-28 1994-06-07 The Dow Chemical Company Sample probe
US5605798A (en) * 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
DE69430909T2 (en) * 1993-03-19 2003-02-27 Sequenom, Inc. DNA SEQUENCE DETERMINATION BY MASS SPECTROMETRY ON THE WAY OF DEGRADATION WITH EXONUCLEASE
US20020037517A1 (en) * 1993-05-28 2002-03-28 Hutchens T. William Methods for sequencing biopolymers
WO1996037777A1 (en) * 1995-05-23 1996-11-28 Nelson Randall W Mass spectrometric immunoassay
CA2221250C (en) * 1995-06-07 2007-11-20 Arizona Board Of Regents A sample presentation apparatus for mass spectrometry
EP1046036A4 (en) 1997-07-29 2003-08-27 James S Huston Methods for obtaining probes of peptide function
CN1204592C (en) * 1999-04-27 2005-06-01 赛弗根生物系统股份有限公司 Probes for gas phase ion spectrometer

Patent Citations (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022876A (en) * 1973-06-21 1977-05-10 Stanford Research Institute Mass spectrometric immunoassay
US3896661A (en) * 1974-01-09 1975-07-29 Stanford Research Inst Method of coupling thin layer chromatograph with mass spectrometer
US4295046A (en) * 1975-09-11 1981-10-13 Leybold Heraeus Gmbh Mass spectrometer
US4298332A (en) * 1978-04-08 1981-11-03 Katashi Aoki Nozzle device for molding plastics
US4296332A (en) * 1979-12-28 1981-10-20 Sperry Corporation Sprocket hole sensing detector for moving translucent paper sheets
US4468468A (en) * 1981-06-27 1984-08-28 Bayer Aktiengesellschaft Process for the selective analysis of individual trace-like components in gases and liquid
US4454233A (en) * 1981-10-21 1984-06-12 Wang Associates Method of tagged immunoassay
US5124267A (en) * 1984-05-10 1992-06-23 Schering Aktiengesellschaft Method for the determination of small substance quantities of medicines, of endogenous or other chemical compounds in biological material
US4902627A (en) * 1985-02-05 1990-02-20 The United States Of America As Represented By The Secretary Of The Navy Method for detecting amine-containing drugs in body fluids by sims
US4686366A (en) * 1985-05-15 1987-08-11 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Laser mass spectrometer
US4694167A (en) * 1985-11-27 1987-09-15 Atom Sciences, Inc. Double pulsed time-of-flight mass spectrometer
US4705616A (en) * 1986-09-15 1987-11-10 Sepragen Corporation Electrophoresis-mass spectrometry probe
US4988879A (en) * 1987-02-24 1991-01-29 The Board Of Trustees Of The Leland Stanford Junior College Apparatus and method for laser desorption of molecules for quantitation
US5003059A (en) * 1988-06-20 1991-03-26 Genomyx, Inc. Determining DNA sequences by mass spectrometry
US5078135A (en) * 1989-05-31 1992-01-07 Board Of Regents, The University Of Texas System Apparatus for in vivo analysis of biological compounds in blood or tissue by microdialysis and mass spectrometry
US5118937A (en) * 1989-08-22 1992-06-02 Finnigan Mat Gmbh Process and device for the laser desorption of an analyte molecular ions, especially of biomolecules
US5045694A (en) * 1989-09-27 1991-09-03 The Rockefeller University Instrument and method for the laser desorption of ions in mass spectrometry
US5209919A (en) * 1990-07-13 1993-05-11 Regents Of The University Of California Method of measurement in biological systems
US5171989A (en) * 1992-01-24 1992-12-15 Board Of Trustees Of Leland Stanford Jr. University Method and apparatus for continuous sample ice matrix production for laser desorption in mass spectrometry
US5547835A (en) * 1993-01-07 1996-08-20 Sequenom, Inc. DNA sequencing by mass spectrometry
US5894063A (en) * 1993-05-28 1999-04-13 Baylor College Of Medicine Surface-enhanced neat desorption for disorption and detection of analytes
US5719060A (en) * 1993-05-28 1998-02-17 Baylor College Of Medicine Method and apparatus for desorption and ionization of analytes
US6027942A (en) * 1993-05-28 2000-02-22 Baylor College Medicine Surface-enhanced affinity capture for desorption and detection or analytes
US6124137A (en) * 1993-05-28 2000-09-26 Baylor College Of Medicine Surface-enhanced photolabile attachment and release for desorption and detection of analytes
US6528320B2 (en) * 1993-05-28 2003-03-04 Baylor College Of Medicine Method and apparatus for desorption and ionization of analytes
US6734022B2 (en) * 1993-05-28 2004-05-11 Baylor College Of Medicine Method and apparatus for desorption and ionization of analytes
US6020208A (en) * 1994-05-27 2000-02-01 Baylor College Of Medicine Systems for surface-enhanced affinity capture for desorption and detection of analytes
US6225047B1 (en) * 1997-06-20 2001-05-01 Ciphergen Biosystems, Inc. Use of retentate chromatography to generate difference maps
US6579719B1 (en) * 1997-06-20 2003-06-17 Ciphergen Biosystems, Inc. Retentate chromatography and protein chip arrays with applications in biology and medicine
US6811969B1 (en) * 1997-06-20 2004-11-02 Ciphergen Biosystems, Inc. Retentate chromatography—profiling with biospecific interaction adsorbents
US6844165B2 (en) * 1997-06-20 2005-01-18 Ciphergen Biosystems, Inc. Retentate chromatography and protein chip arrays with applications in biology and medicine
US6881586B2 (en) * 1997-06-20 2005-04-19 Ciphergen Biosystems, Inc. Retentate chromatography and protein chip arrays with applications in biology and medicine
US6228047B1 (en) * 1997-07-28 2001-05-08 1274515 Ontario Inc. Method and apparatus for performing peritoneal dialysis

Also Published As

Publication number Publication date
CA2163426C (en) 2005-11-01
US20010014479A1 (en) 2001-08-16
US5719060A (en) 1998-02-17
PT700521E (en) 2003-10-31
US6528320B2 (en) 2003-03-04
US20020155620A1 (en) 2002-10-24
DK0700521T3 (en) 2003-09-29
EP1347493A9 (en) 2003-12-17
AU7048394A (en) 1994-12-20
US7449150B2 (en) 2008-11-11
JP3639594B2 (en) 2005-04-20
NZ267842A (en) 1997-09-22
WO1994028418A1 (en) 1994-12-08
EP0700521A4 (en) 1997-06-11
US5894063A (en) 1999-04-13
JP3457228B2 (en) 2003-10-14
EP1347493A2 (en) 2003-09-24
JP3818990B2 (en) 2006-09-06
ES2201077T3 (en) 2004-03-16
DE69432791T2 (en) 2004-06-03
EP1347493A3 (en) 2005-11-23
JPH09501489A (en) 1997-02-10
EP0700521B1 (en) 2003-06-04
DE69432791D1 (en) 2003-07-10
CA2512290C (en) 2010-02-02
US6734022B2 (en) 2004-05-11
US6027942A (en) 2000-02-22
JP2004004124A (en) 2004-01-08
US20010023074A1 (en) 2001-09-20
CA2163426A1 (en) 1994-12-08
ATE242485T1 (en) 2003-06-15
JP2000131285A (en) 2000-05-12
AU676582B2 (en) 1997-03-13
EP0700521A1 (en) 1996-03-13
US20060134797A1 (en) 2006-06-22
US6124137A (en) 2000-09-26
CA2512290A1 (en) 1994-12-08
US7071003B2 (en) 2006-07-04

Similar Documents

Publication Publication Date Title
US5894063A (en) Surface-enhanced neat desorption for disorption and detection of analytes
US6020208A (en) Systems for surface-enhanced affinity capture for desorption and detection of analytes
US7413909B2 (en) Method and apparatus for desorption and ionization of analytes
JP3930563B2 (en) Surface plasmon resonance mass spectrometry
EP3306310B1 (en) Method for quantifying monoclonal antibody
JP2001281222A (en) Analytical method for object to be analyzed by mass spectrometry
EP4241083A1 (en) Derivatization of at least one analyte of interest for mass spec measurements in patient samples

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION